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The heat shock protein 90 and 70 (Hsp90 and Hsp70) chaperone system maintains protein 
quality control for over one hundred client proteins, including many implicated in 
neurodegenerative disorders, by surveilling substrate binding clefts and selectively targeting 
damaged proteins for degradation. Hsp90 stabilizes client proteins in their native state and prevents 
degradation, whereas Hsp70 facilitates ubiquitination by E3 ligases and promotes proteasomal 
degradation. Traditionally the chaperone system has been targeted with Hsp90 inhibitors, and 
while many Hsp90 inhibitors have entered clinical trials for cancer they have failed to progress 
due in part to toxicity. Activation of Hsp70 has recently emerged as an alternative approach, with 
numerous genetic studies demonstrating that activation of Hsp70-dependent ubiquitination 
increases the degradation of disease-causing client proteins in cellular and animal models. Studies 
on the pharmacological activation of Hsp70 have been limited by the small number of compounds 
known to activate Hsp70-dependent ubiquitination. Thus, an innovative workflow was developed 
to discover novel small molecule activators of Hsp70. A high-throughput Hsp70 thermal shift 
assay and Hsp90 counter screen were utilized to identify compounds that bind and thermostabilize 
Hsp70. To test the functional effect of Hsp70 thermostabilizers in vitro, a purified protein system 
for Hsp70-dependent ubiquitination of neuronal nitric oxide synthase (nNOS) and a highly 
sensitive ELISA for the measurement of nNOS ubiquitination were established. With the use of 
this workflow we successfully identified one novel small molecule activator of Hsp70-dependent 
ubiquitination. Moreover, in the course of these studies we discovered pharmacological activation 
of Hsp70 can selectively increase the ubiquitination of damaged nNOS over nNOS in its native 
 ix 
state. The small molecule identified by this workflow increases the structural diversity of 
compounds known to activate Hsp70-dependent ubiquitination and may provide a valuable tool to 
advance the study of pharmacological activation of Hsp70 as a therapeutic strategy.  
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Chapter 1 : Targeting Hsp70 facilitated protein quality control for treatment of 
polyglutamine diseases 
 
This chapter has been previously published in Cell and Molecular Life Sciences  2019 Sep 24. doi: 
10.1007/s00018-019-03302-2. [Epub ahead of print] 
Abstract 
The polyglutamine (polyQ) diseases are group of nine fatal, adult-onset neurodegenerative 
disorders characterized by the misfolding and aggregation of mutant proteins containing toxic 
expansions of CAG/polyQ tracts. The heat shock protein 90 and 70 (Hsp90/Hsp70) chaperone 
machinery is a key component of cellular protein quality control, playing a role in the regulation 
of folding, aggregation, and degradation of polyQ proteins. The ability of Hsp70 to facilitate 
disaggregation and degradation of misfolded proteins makes it an attractive therapeutic target in 
polyQ diseases. Genetic studies have demonstrated that manipulation of Hsp70 and related co-
chaperones can enhance the disaggregation and/or degradation of misfolded proteins in models of 
polyQ disease.  Therefore, the development of small molecules that enhance Hsp70 activity is of 
great interest. However, it is still unclear if currently available Hsp70 modulators can selectively 
enhance disaggregation or degradation of misfolded proteins without perturbing other Hsp70 
functions essential for cellular homeostasis. This review discusses the multifaceted role of Hsp70 
in protein quality control and the opportunities and challenges Hsp70 poses as a potential 
therapeutic target in polyQ disease. 
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Introduction 
Age-dependent protein aggregation disorders are characterized by the accumulation of 
damaged or mutant proteins in the central nervous system, most often in neurons. The preferential 
accumulation of misfolded proteins in neurons underscores the importance of protein quality 
control mechanisms, such as the heat shock protein 90 and 70 (Hsp90/Hsp70) chaperone 
machinery, in neuronal homeostasis. The polyglutamine (polyQ) diseases are an example of 
hereditary protein aggregation disorders and include Huntington disease (HD), spinal bulbar 
muscular atrophy (SBMA/Kennedy disease), dentatorubral pallidoluysian atrophy (DRPLA), and 
six autosomal dominant forms of spinocerebellar ataxia (SCAs) [1]. These diseases are caused by 
the expansion of CAG/polyQ tracts in a collection of unrelated proteins, and penetrance only 
occurs once polyQ length exceeds disease-specific thresholds. Additional disorders in which 
expanded CTG repeats are associated with antisense transcripts containing long CAG repeats have 
also been described [2]. Proteins containing disease length polyQ tracts are prone to misfolding 
and can self-assemble into soluble oligomers and microaggregates that coalesce into insoluble, 
amyloid-like fibrils. The polyQ length threshold for disease penetrance is strikingly correlated to 
the threshold for aggregation of polyQ proteins in vitro [3]. It is well established the misfolding of 
polyQ containing proteins drives disease. While the exact specie(s) of polyQ proteins that mediate 
toxicity is unclear, the accumulation and aggregation of misfolded polyQ proteins in neurons 
implies that aggregate formation overwhelms protein quality control as an underlying basis of 
disease. 
The role of the Hsp90/Hsp70 chaperone machinery in protein quality control has been well 
studied in the context of HD, SBMA, and SCA3. Therefore, this review will focus on these three 
polyQ diseases as representatives of the whole group, with additional examples provided when 
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relevant.  HD, the most prevalent of the polyQ diseases, is caused by mutant huntingtin (Htt) 
harboring an expanded polyQ tract [4]. The normal function of Htt is incompletely understood, 
however recent work suggests it acts as a scaffold in retrograde transport, vesicle trafficking, and 
selective autophagy [5]. PolyQ Htt-dependent neuron dysfunction and death causes progressive 
motor, cognitive, and psychiatric manifestations in HD patients. SBMA is a neuromuscular 
degenerative disorder that is characterized by progressive weakness of proximal limb and bulbar 
muscles [6]. SBMA is caused by a polyQ expansion in the androgen receptor (AR) and 
pathogenesis is dependent on circulating levels of androgen; therefore, the disease only affects 
males. Steroid hormone-dependent translocation of polyQ AR to the nucleus leads to ligand-
dependent misfolding and formation of nuclear inclusions. PolyQ proteins cause degeneration of 
the cerebellum in six forms of SCA [7]. The most common polyQ SCA, SCA3, is caused by the 
expansion of a polyQ tract in ataxin-3 (ATXN3), a deubiquitinating enzyme [8]. All polyQ 
diseases are ultimately fatal, with disease onset typically occurring in mid-life and disease 
progression occurring over the next 10 to 30 years [9]. Even though the genetic cause and 
progression of these diseases are well understood, there are currently no FDA-approved disease-
modifying treatments. 
A large body of work has demonstrated that genetic manipulation of the Hsp90/Hsp70 
chaperone machinery is therapeutically beneficial in cellular and animal models of polyQ disease 
[10, 11], making the Hsp90/Hsp70 chaperone machinery an attractive therapeutic target. There are 
two main pharmacological strategies for targeting this system: inhibition of Hsp90 and activation 
of Hsp70. While it is well established that cycling into complexes with Hsp90 stabilizes Hsp90 
client proteins, such as the AR and Htt and that specific inhibition of Hsp90 enhances client protein 
degradation, this approach has the potential to cause on-target side effects due a global decrease 
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in the hundreds of proteins reliant on Hsp90 for stabilization [10]. Activation of Hsp70, on the 
other hand, is focused on selectively enhancing the disaggregation and degradation of already 
misfolded proteins and should not affect properly folded Hsp90-dependent proteins, thus 
minimizing side effects. Hsp70 selectively facilitates the degradation of misfolded proteins, thus 
activation of Hsp70-facilitated degradation may provide a strategy to eliminate misfolded proteins 
while leaving native proteins untouched. However, targeting Hsp70 is not without problems. To 
be therapeutically beneficial a small molecule must selectively enhance the anti-aggregation or 
pro-degradative activity of Hsp70, without disrupting other Hsp70 functions critical for cellular 
homeostasis. Hsp70 activity is dependent on a conformational cycle determined by nucleotide 
binding, hydrolysis, and release, and this cycle is adapted to specific functions through regulation 
by co-chaperones. Indeed, co-chaperone binding sites may provide targets for small molecules that 
alter Hsp70 function. Designing small molecules that selectively alter one Hsp70 function while 
leaving others untouched poses a challenge. This review will focus on the role of Hsp70 in protein 
quality control and the opportunity and obstacles it presents as a therapeutic target in polyQ 
disease; Hsp90 will be discussed only in context of its cooperation with Hsp70, as comprehensive 
reviews on Hsp90 are available.   
Hsp70 function is driven by nucleotide cycling and regulated by co-chaperones 
Heat shock proteins (Hsp) were first discovered due to their increased expression upon heat 
exposure [12, 13]. These proteins were originally named based on  their molecular weight and 
include Hsp110 (HSPH), Hsp90 (HSPC), Hsp70 (HSPA1), Hsp60 (chaperonins), Hsp40 (J-
domain/DNAJ), and small heat shock proteins (sHsp/HspB) [14]. It is now recognized that several 
environmental and pathological conditions, not just heat, can induce the expression of Hsps, 
underscoring their importance in the response to cellular stress. The transcription factor HSF1 
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(heat shock factor 1) is the master regulator of the heat shock response (HSR). Under conditions 
of stress, localization of HSF1 to the nucleus and binding to the heat shock element in promoters 
leads to the activation of genes encoding inducible members of the Hsp90/Hsp70 chaperone 
machinery [15, 16]. Hsp families include constitutively expressed members, such as Hsc70 in the 
Hsp70 family, and therefore also play a role in protein quality control under basal conditions. To 
further add to the complexity, Hsp families contain numerous members with distinct subcellular 
localization and unique functions. The Hsp70 family alone contains 13 members in humans, 
including the cytoplasmic variants Hsp70 (HSPA1) and Hsc70 (HSPA8), the mitochondrial variant 
mtHsp70 (mortalin/HSPA9), and the endoplasmic reticulum variant BIP (GRO78/HSPA5) [17]. 
In this review the term Hsp70 will be used broadly to refer to all family members, and when 
pertinent, specific family members will be defined. 
Interaction of Hsp70 with client proteins is not dependent on a specific sequence or 
structural motif; instead, Hsp70 interacts with proteins containing exposed hydrophobic stretches 
[18]. These hydrophobic residues are exposed in proteins during their synthesis, in protein folding 
(i.e. ligand binding) clefts, in domains regulating protein-protein interactions, or in misfolded 
proteins. Hsp70 is comprised of two domains, a nucleotide binding domain (NBD) and a substrate 
binding domain (SBD), connected by a flexible linker. The action of Hsp70 is facilitated by a 
nucleotide-dependent conformational cycle. In the ATP state, the SBD is docked to the NBD, 
locking Hsp70 into a conformation that has low affinity for unfolded, hydrophobic substrate (Fig. 
1-1a). Upon hydrolysis of ATP to ADP a large conformational change allows the SBD to move 
freely, and in the ADP state Hsp70 exhibits high affinity for unfolding proteins, reviewed in [19] 
(Fig. 1-1b). However, the intrinsic ATPase activity of Hsp70 is very low, with ATP hydrolysis 
being the rate limiting step [20].  
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ATP hydrolysis is stimulated by the J-domain family of co-chaperones (Fig. 1-1b) [21]. 
Nucleotide exchange factors (NEFs), including the Hsp110 and Bcl-2-associated athanogene 
(BAG) families, are co-chaperones that promote the release of ADP from Hsp70 and allow for the 
binding of a new ATP molecule and the continuation of the cycle (Fig. 1-1c) [22].  The nucleotide 
cycle of Hsp70 is further regulated by the co-chaperone HIP (Hsp70 interacting protein). HIP binds 
to the NBD of Hsp70 in the ADP-bound state via a tetratricopeptide repeat (TPR) domain, and 
HIP binding antagonizes NEF activity (Fig. 1-1c). Therefore, HIP stabilizes the ADP state of 
Hsp70 and increases the amount of time Hsp70 stays bound to a misfolded protein [23]. Through 
the regulation of nucleotide cycling these co-chaperones adapt Hsp70 function to different roles in 
protein quality control. 
Multifaceted role of Hsp70 in protein quality control 
Hsp70 plays a multifaceted role in protein quality control and is adapted to different 
pathways through regulation by co-chaperones (Table 1-1). 
Folding of newly synthesized proteins 
While the Hsp70 family was first recognized for its role in stress response, the constitutive 
members of the family also play a critical role in protein quality control during basal conditions, 
including the folding of newly synthesized protein. In vitro many proteins can fold spontaneously 
[24]; however, larger proteins and proteins with a high abundance of disordered regions require 
the assistance of chaperones to properly fold in the crowded cellular environment [25]. The 
constitutive form of Hsp70, Hsc70, works in concert with specialized J-domain proteins and NEFs 
to prevent the misfolding of newly synthesized proteins by cycling with the nascent chain as it 
exits the ribosome, a process known as co-translational folding [26–29]. Binding of Hsc70 
stabilizes the unfolded state of the newly synthesized protein and can even reverse misfolded states 
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[30]. Subsequent release of the stabilized protein from Hsc70 allows folding to proceed in the 
correct order, starting with secondary structure [31]. Under conditions of proteotoxic stress, such 
as proteasome inhibition, Hsc70 is sequestered from the ribosomes by a build-up of misfolded 
proteins, resulting in the misfolding of newly synthesized proteins and inhibiting global protein 
synthesis [32]. The expression of a dominant-negative Hsp70 (K71M), incapable of nucleotide 
cycling, or treatment with the Hsp70 inhibitors VER-155008 (VER) or Pifithrin-µ (PES) also 
decreases global protein synthesis  [32], demonstrating the importance of Hsc70 for protein quality 
control under homeostatic conditions. 
Maturation of Hsp90 client proteins 
Along with Hsp90 itself, Hsp70 is an essential member of the multiprotein chaperone 
machinery that facilitates the maturation of Hsp90 client proteins. Several hundred Hsp90 client 
proteins have been identified, including many signaling proteins such as protein kinases and 
steroid receptors [10, 33]. Hsp90 interacts with client proteins at regions where hydrophobic amino 
acids are exposed to solvent, such as where ligand binding clefts fuse with the charged protein 
surface, stabilizing the cleft in an active conformation for ligand binding and stabilizing the protein 
[34]. For steroid receptors, such as AR, proper folding of the ligand binding cleft, insertion of 
steroid (Fig. 1-2a), translocation to the nucleus (Fig. 1-2b) and therefore transcriptional activity 
requires the Hsp90 chaperone machinery. This machinery has been studied in detail with 
relationship to the glucocorticoid receptor (GR), as reviewed in [35]. In the first step of this 
machinery’s function, Hsp70 in the ATP state [36] interacts with the closed (folded) ligand binding 
cleft of the steroid receptor and subsequent ATP hydrolysis (promoted by DNAJ proteins) partially 
unfolds the cleft, priming it for interaction with Hsp90 [37, 38]. The co-chaperone HOP (Hsp 
Organizing Protein) forms a chaperone machinery by facilitating the interaction of Hsp70 and 
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Hsp90. This interaction occurs through binding of an N-terminal and central TPR domain to EEVD 
motifs on the C-terminus of Hsp70 and Hsp90 [39], promoting the transfer of the steroid receptor 
from Hsp70 to Hsp90 [40]. Subsequent ATP dependent cycling of Hsp90 leaves the cleft in an 
open state and binding of p23 to Hsp90 [41] stabilizes the cleft in an open conformation, allowing 
for the insertion of steroid [33]. The ATPase dead Hsp70 mutant K71M fails to facilitate the 
assembly of the multichaperone machinery with the progesterone receptor (PR) [42], and 
inhibition of Hsp70 by methylene blue (MB) inhibits steroid binding activity of GR, demonstrating 
Hsp70 is necessary for the proper function of the Hsp90 multichaperone machinery [43].  Steroid 
insertion leads to rapid retrograde transport of steroid receptors to the nucleus by an Hsp90-
immunophilin-dynein complex and passage through nuclear pores in an importin-dependent 
process, as reviewed in [44]. For polyQ AR, the conformational change induced by steroid 
insertion causes misfolding and translocation of the misfolded protein to the nucleus, leading to 
the formation of nuclear aggregates. Either genetic or pharmacological inhibition of Hsp90 reduces 
ligand-dependent nuclear translocation of polyQ AR and decreases polyQ AR nuclear aggregates 
[45]. 
Proteasomal Degradation 
The chaperone machinery plays a critical role in protein quality control by selectively 
recognizing misfolded proteins and targeting them for degradation by the ubiquitin proteasome 
system (UPS) [46]. Ubiquitination is a post translational modification by which an 8.6 kDa 
ubiquitin protein is covalently added to a protein; ubiquitination can target a protein to numerous 
cellular pathways including degradation by the proteasome. Hsp90 and Hsp70 play opposing roles 
in the triage of misfolded proteins, as reviewed in [46]. Hsp90 stabilizes proteins in a near-native 
state, protecting them from degradation. In contrast, if a protein is too misfolded to be stabilized 
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by Hsp90, then Hsp70 facilitates ubiquitination by chaperone dependent E3 ubiquitin ligases, such 
as CHIP (C-terminus of Hsp70 interacting protein), a TPR domain containing protein that binds 
the EEVD domain on the C-terminus of Hsp70 (Fig. 1-2c) [47, 48]. CHIP interacts with E2 
ubiquitin conjugating enzymes, through a C-terminal U box domain, and ubiquitinates proteins 
bound to Hsp70 [49]. Numerous co-chaperones promote Hsp70-mediated proteasomal degradation 
of misfolded proteins. For example, the J-domain protein DNAJB2 (HSJ1) recruits misfolded 
proteins to Hsp70 and promotes ubiquitination by CHIP [50], then DNAJB2 targets the 
ubiquitinated proteins to the proteasome via ubiquitin interaction motifs (UIMs) [50, 51]. The NEF 
BAG1 also promotes Hsp70-mediated proteasomal degradation. BAG1 contains a ubiquitin like 
domain that allows it to associate with the proteasome and promote the release of Hsp70-bound 
ubiquitinated proteins to the proteasome [52, 53]. Hsp70-mediated ubiquitination and degradation 
has been shown to regulate the turnover of polyQ disease-related proteins, including AR, Htt, and 
ATXN3 as well as non-polyQ proteins implicated in age dependent neurodegenerative disorders 
such as tau and α-synuclein [10, 11] 
Autophagy 
Hsp70 can also target misfolded proteins to degradation through autophagy, a process by 
which proteins are degraded in lysosomes. Proteins destined for degradation by autophagy are 
delivered to the lysosome by different mechanisms. In macroautophagy, cargo is transported to 
lysosomes inside double membrane vesicles known as autophagosomes [54]. Chaperone-assisted 
selective autophagy (CASA) is a form of macroautophagy which utilizes Hsp70 to target proteins 
to the autophagosome. In microautophagy the lysosomal membrane invaginates and pinches off to 
form vesicles that internalize autophagic cargo [55]. Proteins can also enter the lysosome through 
a protein translocation system embedded in the lysosomal membrane in a process known as 
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chaperone-mediated autophagy (CMA) [56]. Autophagy has been shown to play an important role 
in the degradation of polyQ proteins including AR, Htt, and ATXN3 [57]. Autophagy can facilitate 
the degradation of protein species that are not amenable to degradation by the proteasome, such as 
insoluble polyQ aggregates and proteolytic fragments of polyQ proteins. For example, N-terminal 
fragments of polyQ AR are toxic species that lack the ligand binding domain, the site of  
recognition by the Hsp90/Hsp70 chaperone machinery, and therefore are not readily targeted to 
the proteasome, being preferentially degraded by autophagy [43]. N-terminal fragments of polyQ 
Htt also contribute to toxicity in HD and are preferentially degraded by autophagy [57, 58]. 
Chaperone-mediated autophagy (CMA). In CMA, proteins containing a KFERQ-like 
pentapeptide motif, present in approximately 40% of the mammalian proteome, are targeted to 
degradation in the lysosome by Hsp70 [59, 60]. Hsp70 binds to the KFERQ domain and targets 
the protein to the lysosomal membrane, where the protein then binds to LAMP2A (lysosome 
associated membrane protein type 2A). The target protein is subsequently unfolded and then 
translocated into the lysosomal lumen [61–63] through the CMA translocon complex, which 
consists of a trimer of LAMP2A [64]. CMA is observed at low levels under homeostatic conditions 
in most cells, but upon stress, CMA activity significantly increases, highlighting the importance 
of this pathway as a compensatory mechanism for proteotoxic stress [61]. Upregulation of CMA 
activity has been observed in cellular and animal models of polyQ disease [65] and has been shown 
to promote the clearance of polyQ Htt [66] and polyQ Atxn7, the disease-causing protein in SCA7 
[67]. 
Chaperone-assisted endosomal microautophagy (eMI). Proteins containing the KFERQ-
like pentapeptide motif can also be targeted by Hsc70 to the late endosome for degradation by 
microautophagy. In eMI proteins do not enter the late endosome through a translocon; instead,  the 
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endosomal membrane invaginates to trap cytosolic proteins for degradation [61]. Therefore, unlike 
CMA, which requires proteins to be unfolded before translocation,  chaperone assisted eMI can 
facilitate the degradation of proteins that are folded, in early stages of misfolding and aggregation, 
or assembled into higher order aggregation complexes [68]. Hsp70 binds the pentapeptide-
containing protein and recruits the protein to the endosomal membrane by binding of a unique site 
on the lid of Hsp70 to phosphatidylserine moieties [69]. Hsp70 and its cargo are then  internalized 
in ESCRT-mediated microvesicles [68]. 
Chaperone-assisted selective autophagy (CASA). Hsp70 also plays a role in assembly of 
the presentation complex responsible for selectively targeting proteins to the forming 
autophagosome for degradation by macroautophagy (Fig. 1-2e) [52]. BAG3 and HspB8 connect 
Hsp70 to the macroautophagy pathway [70, 71]. First, BAG3 binds Hsp70 in complex with CHIP 
and ubiquitinated substrate via its BAG domain and then binds the small Hsp, HspB8, through an 
IPV motif [72]. BAG3 then interacts with dynein to facilitate the transport of the misfolded protein 
containing CHIP-Hsp70-BAG3-HspB8 complex to the aggresome at the MTOC (microtubule 
organization center), a region highly enriched in autophagy/lysosomal pathway components. This 
complex then interacts with the macroautophagy receptor protein p62, which targets the 
ubiquitinated, misfolded protein to the autophagosome via the autophagosome membrane-
associated protein LC3 [73]. The autophagosome then fuses to the lysosome where the misfolded 
protein is degraded. In a motoneuronal cell model of SBMA it was demonstrated that polyQ AR-
induced proteotoxic stress leads to an upregulation of HspB8, promoting the clearance of cytosolic 
polyQ AR aggregates by autophagy [74]. 
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Disaggregation 
Hsp70 in collaboration with specialized J-domain proteins and the Hsp110 family of NEFs 
can disaggregate and solubilize misfolded proteins (Fig. 1-2d) [75, 76]. While the structure and 
composition of the DNAJ-Hsp70-Hsp110 disaggregase complex is still debated, the current 
‘nucleation’ model suggests that complex formation is initiated by the recruitment of multiple 
Hsp70s to the surface of aggregates by J-domain proteins [77]. J-domain proteins belonging to 
class A and B, such as DNAJB1 (HDJ1), have been implicated in the targeting of Hsp70 to 
aggregates [78, 79]. Both class B and A J-domain proteins have high homology to the canonical 
E. coli J-domain protein, DNAJ, and contain a conserved N-terminal J-domain responsible for 
promoting ATPase activity [17]. However, their C-terminal domains differ in structure and confer 
unique substrate specificity [21]. In addition to recruiting Hsp70 to the aggregate surface, J-domain 
proteins also stimulate ATPase activity. This allows for the binding of Hsp70 to the exposed 
hydrophobic residues on the ends of aggregated proteins and, through a process known as entropic 
pulling, liberation of polypeptides from the protein aggregate. Members of the Hsp110 family then 
reset the disaggregase machinery by promoting dissociation of ADP, allowing for a new round of 
ATP hydrolysis [80]. It appears that only members of the HSP110 family of NEFs participate in 
Hsp70-mediated disaggregation [79]. Ubiquilin-2 (UBQLN2) interacts with misfolded proteins 
liberated from aggregation, through an ubiquitin-associated domain, and targets them to the 
proteasome via an ubiquitin-like domain [81]. UBQLN2 has been shown to work together with 
the DNAJ-Hsp70-Hsp110 disaggregase complex to promote the proteasomal degradation of polyQ 
Htt in cellular and mouse models of HD [82]. Interestingly some J-domain proteins, including 
DNAJB6 and DNAJB8, have been shown to directly interact with and prevent aggregation of 
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polyQ proteins in a mechanism independent of the DNAJ-Hsp70-Hsp110 disaggregase complex 
[83, 84]. 
When it comes to aggregation, most research has focused on Hsp70’s ability to disassemble 
toxic inclusions of polyQ proteins. However, it is important to keep in mind that controlled 
sequestration of polyQ proteins can be cytoprotective and Hsp70 also plays a regulatory role in 
the formation of polyQ aggregates. For example, in a mechanism overlapping with CASA, Hsp70 
interacts with dynein motors, in a BAG3-dependent manner [73], to direct retrograde transport of 
misfolded proteins along microtubules to an aggresome, located at the MTOC [85]. Sequestration 
of misfolded proteins into the aggresome promotes their clearance by autophagy. 
Dysregulation of protein quality control in polyglutamine disease 
Dysregulation of the Hsp90/Hsp70 chaperone machinery, the ubiquitin proteasome system, 
and autophagy leads to diminished protein quality control and accumulation of misfolded proteins 
in polyQ disease [58, 86]. Disease progression correlates with a decrease in key members of the 
Hsp90/Hsp70 chaperone machinery in HD, SBMA, and SCA17 [87–89]. One mechanism by 
which polyQ proteins decrease chaperone levels is through the sequestration of chaperones and 
related transcription factors into aggregates. For example, levels of soluble DNAJB1 decline over 
time in the brains of an HD mouse model due to direct sequestration of DNAJB1 into nuclear 
polyQ Htt aggregates [90]. Consistent with these observations, DNAJB1 also co-localizes with 
aggregates in a cellular model of SCA3 [91]. In yeast, it has been demonstrated that sequestration 
of DNAJB1 into aggregates prevents the co-chaperone from targeting misfolded proteins to the 
proteasome [92]. Hsp70 levels also progressively decline in mouse models of HD. However, this 
decline is not due to direct sequestration of Hsp70: instead, polyQ Htt aggregates sequester the 
transcription factor NF-Y leading to decreased expression of Hsp70 [93]. Sequestration of NF-Y 
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by aggregates was also shown to decrease Hsp70 expression in a cellular model of SCA17 [94]. 
These findings suggest that sequestration of chaperones, and the transcription factors that regulate 
their expression, is a shared mechanism by which polyQ proteins disrupt the function of the 
chaperone machinery. 
Accumulation and aggregation of misfolded proteins activates the HSF1-driven HSR, 
inducing expression of the Hsp90/Hsp70 chaperone machinery. However, in HD, the HSR is 
greatly diminished in large part, by polyQ Htt-dependent dysregulation of HSF1. For example, 
cells expressing polyQ Htt have decreased expression of HSF1 and impaired HSR [95]. Consistent 
with these findings, HSF1 and Hsp70 levels are reduced in the striata of HD knock-in mice 
compared to wildtype mice [95]. One mechanism by which polyQ Htt decreases HSF1 levels is 
through the upregulation of CK2α' kinase and Fbxw7 E3 ligase levels, increasing phosphorylation 
and proteasomal degradation of HSF1 [14]. In contrast, other studies in both cellular and animal 
models of HD have not observed changes in HSF1 levels, and instead conclude that altered 
chromatin structure leads to decreased binding of HSF1 to heat shock response elements and 
impaired HSR [96, 97]. It is unclear if diminished HSR is a common mechanism amongst all polyQ 
diseases, but HSR impairment has been observed in other protein folding diseases such as 
Parkinson disease [98, 99]. Activation of HSR by HSF1 modulators has been shown to alleviate 
toxicity in both cellular and animal models of polyQ-disease and is therefore being investigated as 
a potential therapeutic strategy, as reviewed in [11]. Further work is needed to evaluate the long 
term consequences of pharmacological activation of HSR, as some studies have found that chronic 
activation of HSR can exacerbate toxicity in cellular models of protein misfolding disease 
including HD [100] and Alzheimer’s disease [101]. 
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Dysregulation of the ubiquitin proteasome system is also observed in polyQ disease. The 
Hsp90/Hsp70 chaperone machinery selectively targets misfolded proteins for degradation by the 
proteasome; therefore, polyQ proteins have an accelerated turnover. This concept is highlighted 
by cellular experiments where proteasome inhibition causes a greater build-up of ubiquitinated 
proteins in cells expressing disease length versus wildtype AR and Htt [102, 103]. In polyQ disease 
it is thought that the increase in proteins targeted for degradation overwhelms the capacity of the 
proteasome, thus contributing to the accumulation of polyQ proteins [104]. Consistent with this 
hypothesis ubiquitinated polyQ Htt has been shown to accumulate in the brains of both HD mouse 
models and patients [105].  This build-up of polyQ proteins has also been shown to compete with 
other proteasome substrates for a limited degradation capacity. For example, expression of polyQ 
Htt and Atxn7 in cells has been shown to decrease the degradation of other non-polyQ proteasome 
substrates [106, 107]. Therefore, the cell has decreased ability to respond to proteotoxic stress 
[108]. PolyQ proteins can also decrease function of the ubiquitin proteasome system by decreasing 
the expression of key proteasome components. For example, in a mouse model of SBMA, polyQ 
AR diminished activity of the proteasome transcription factor NRF1 (nuclear factor erythroid 1) 
in skeletal muscle in a hormone- and polyQ-tract length-dependent manner, resulting in decreased 
degradation capacity and a build-up of dysfunctional proteasomes in mutant muscle [109]. Taken 
together these findings demonstrate that dysregulation of the ubiquitin proteasome system is a 
compounding factor in the accumulation of misfolded proteins in polyQ disease.  
The proteotoxic stress induced by the accumulation of misfolded proteins has been shown 
to alter autophagic pathways. For example, expression of misfolded proteins or pharmacological 
inhibition of the proteasome causes a robust increase in HspB8 expression. In contrast, other 
stressors such as serum starvation and heat shock do not alter HspB8 levels, demonstrating this 
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compensation is specific to proteasome impairment [70, 71]. Both HspB8 and BAG3, co-
chaperones that facilitate CASA, are upregulated in polyQ AR knock-in mice [110]. It has been 
demonstrated that upregulation of HspB8 increases the clearance of cytosolic polyQ AR and 
reduces toxicity in a motorneuron cellular model of SBMA [74], consistent with the hypothesis 
that enhancement of autophagy is a beneficial compensatory mechanism to restore proteostasis. 
However other studies have demonstrated that activation of autophagy is in fact a maladaptive 
response in SBMA. For example, the activity of the transcriptional factor EB (TFEB) is 
upregulated in the muscle of polyQ AR knock-in mice leading to an increase in autophagic flux 
[110, 111]. Activation of autophagy has been shown to increase muscle atrophy in the same mouse 
model of SBMA [112] whereas genetic inhibition of autophagy decreased muscle atrophy and 
expanded lifespan [112]. In contrast to findings in SBMA, it has been demonstrated that down 
regulation of autophagy contributes to diminished protein quality control in HD [11, 113]. For 
example, transcriptional dysregulation of autophagy-related genes, including TFEB, has been 
observed in the brains of HD mouse models and patients [114, 115]. PolyQ Htt has also been 
shown to directly impair cargo recognition and engulfment of cytosoplamic cargo [116, 117]. 
Not all cell types expressing polyQ proteins experience a decrease in quality control. In 
HD, polyQ Htt is expressed ubiquitously in the brain but accumulates preferentially in neurons 
[118]. Interestingly, glial cells such as astrocytes do not experience the same accumulation and are 
therefore resistant to the toxicity associated with polyQ proteins [119]. This is thought to be related 
to the capacity of each cell type to degrade misfolded proteins, as astrocytes have been shown to 
degrade polyQ Htt faster than neurons [120]. What differences between neurons and astrocytes 
determines their capacity to degrade misfolded proteins? One explanation is differential expression 
of Hsp70-binding protein 1 (HspBP1) a co-chaperone known to antagonize the action of CHIP 
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[121]. HspBP1 decreases CHIP-dependent ubiquitination of polyQ Htt and subsequent 
proteasomal degradation. Knockdown of HspBP1 enhances degradation of polyQ Htt in cultured 
neurons and reduces polyQ Htt-dependent neuropathology in a mouse model of HD [121]. These 
findings highlight the importance of co-chaperone composition in determining the capacity of the 
protein quality control system in a cell and susceptibility to polyQ protein-mediated toxicity. 
Mutations in Hsp70 co-chaperones lead to neurodegenerative disease 
Is the disruption of Hsp70-mediated protein quality control observed in polyQ disease a 
driving mechanism of toxicity? Rare familial neurodegenerative disorders caused by mutations in 
Hsp70 co-chaperones may shed light on this question. Numerous disease-causing mutations have 
been identified in genes encoding Hsp70 co-chaperones including J-domain, NEF, and HspB 
family members, as reviewed in [100–102]. These rare chaperonopathies can manifest with similar 
muscular and neurodegenerative phenotypes to those observed in polyglutamine disease, 
suggesting that dysfunction of the Hsp90/Hsp70 chaperone machinery may be a common 
underlying mechanism. For example, multiple chaperonopathies are linked to mutations in 
DNAJB2, a J-domain protein shown to work in concert with Hsp70 to shuttle ubiquitinated 
proteins to the proteasome for degradation [50, 51]. A single amino acid substitution in the J-
domain of DNAJB2 causes Charcot Marie Tooth disease type 2 resulting in progressive axonal 
degeneration involving sensory and spinal cord motoneurons [122]. Splicing mutations in 
DNAJB2 that result in either decreased DNAJB2 expression or loss of the J-domain lead to distal 
hereditary motor neuropathies and spinal muscular atrophy, respectively [122, 123]. Mutations in 
another J-domain protein, DNAJB6 (MRJ), shown to potently inhibit the aggregation of misfolded 
proteins [124, 125], cause limb-girdle muscular dystrophy type 1 (LGMD1), a disease 
characterized by the accumulation of abnormal protein aggregates in skeletal muscle fibers and 
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progressive distal greater than proximal muscle atrophy [125, 126]. When expressed in Drosophila, 
human mutations leading to LGMD1 result in a loss of DNAJB6-mediated anti-aggregation [127]. 
These studies suggest that disrupting DNAJ protein function can cause muscular and 
neurodegeneration through dysregulation of pro-degradative and disaggregation functions. 
Mutations in co-chaperones essential to Hsp70-mediated autophagy have also been linked 
to chaperonopathies.  Mutations in BAG3 located in the BAG domain responsible for binding 
Hsp70 or in an isoleucine-proline-valine motif responsible for binding HspB8 cause a dominant 
form of myopathy that is characterized by protein aggregation in skeletal and cardiac muscle [128].  
Characterization of human mutations in vitro demonstrated mutant BAG3 was still capable of 
binding Hsp70, but surprisingly inhibited Hsp70 ATPase activity. Expression of these mutants in 
cells caused aggregation of the mutant BAG3 itself, Hsp70, and ubiquitinated Hsp70 clients and 
impaired CASA [129]. Mutations in HspB8 cause distal hereditary motor neuropathy type II 
(dHMNII), a disease characterized by neuron degeneration in the peripheral nervous system [130, 
131] These HspB8 mutants show decreased interaction with BAG3 [70]. Over-expression of wild 
type HspB8 in cells promotes association of the autophagosome with lysosomes, whereas 
expression of dHMNII HspB8 mutants prevents interaction of the autophagosome and lysosome. 
Consistent with these findings, impaired autophagy was also observed in cells isolated from 
dHMNII patients [131]. These studies demonstrate disruption of a pro-autophagy Hsp70 co-
chaperone leads to muscular and neuronal toxicity. 
Genetic manipulation of Hsp70 and co-chaperones in polyQ disease 
Numerous studies have shown that genetic manipulation of Hsp70 and associated co-
chaperones can ameliorate toxicity in models of polyQ disease by decreasing aggregation or 
increasing degradation of polyQ proteins (reviewed in detail by Reis et al. [11] and Zarouchlioti 
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et al. [126]). These proof-of-concept studies demonstrate that Hsp70 is an attractive therapeutic 
target in polyQ disease. For example, over-expression of Hsp70 reduced aggregation of polyQ AR 
and increased survival in cells [132]. Hsp70 over-expression also reduced aggregation and 
enhanced degradation of polyQ AR in mice, leading to improved motor function [133]. 
Additionally, Hsp70 over-expression improved motor function in a mouse model of SCA1 and 
ameliorated neuropathology in mouse models of both SCA1 and SCA17 [134, 135]. Hsp70 over-
expression shows beneficial but less consistent results in models of HD, and most studies focus 
solely on correlating effects of Hsp70 on polyQ Htt aggregation to toxicity. Over-expression of 
the ER localized Hsc70 homolog BIP [136] and Hsc70 [137], but not Hsp70, reduced polyQ Htt 
aggregation in Neuro2a cells. However, while both BIP and Hsc70 decreased aggregation, only 
over-expression of BIP increased survival. In contrast, over-expression of Hsp70 in HEK293 cells 
had no effect on Htt aggregation but did increase cell survival [138]. Each Hsp70 family member 
plays a unique role in protein quality control, and these experiments highlight the need for further 
work to investigate if specific Hsp70 isoforms offer better therapeutic targets in different polyQ 
diseases. Effects of Hsp70 expression have also been mixed in mouse models of HD. In one 
experiment utilizing R6/2 mice, a transgenic model expressing a small N-terminal fragment of the 
human HD gene containing ~150 CAG repeats, Hsp70 over-expression had no effect on polyQ Htt 
aggregation but delayed weight loss [139], while in another study Hsp70 over-expression caused 
a delay in polyQ Htt aggregation but did not affect disease related phenotypes [90]. However, 
depletion of Hsp70 in R6/2 mice significantly decreased survival and worsened motor dysfunction, 
re-affirming the importance of Hsp70 in the protein quality control of polyQ Htt [140]. This group 
of studies also demonstrates that the effect of Hsp70 on polyQ Htt aggregation is not always 
correlated with survival. While our understanding of the role aggregates play in polyQ protein 
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toxicity is incomplete, these studies suggest that over-expression of Hsp70 may decrease toxicity 
through a mechanism independent of aggregation.  
The role of DNAJ proteins in polyQ diseases has been studied extensively, and family 
members DNAJB1, DNAJB2, and DNAJB6 have been identified as possible therapeutic targets 
[126]. Over-expression of DNAJB1 in Neuro2a cells decreased polyQ Htt inclusion formation, 
and co-expression with Hsp70 reduced toxicity [137, 141]. Similarly, DNAJB1 increased 
solubility and proteasomal degradation of polyQ AR in cells, and co-expression of Hsp70 further 
enhanced DNAJB1 action [132, 142]. Over-expression of the Drosophila DNAJB1 homolog, 
dHDJ1, suppressed polyQ Htt- and ATXN3-dependent toxicity [143, 144], and the effect of 
dHDJ1 on ATXN3-mediated toxicity was enhanced by over-expression with wildtype Hsp70 but 
inhibited by co-expression with a dominant negative mutant of Hsp70. DNAJB2 reduced ATXN3 
levels by promoting proteasomal degradation or stabilizing ATXN3 in an Hsp70-independent 
manner in a cellular model of SCA3 [145]. DNAJB2 decreased polyQ AR inclusions in cells by 
increasing ubiquitination and proteasomal degradation of polyQ AR [51]. DNAJB2 over-
expression decreased polyQ Htt aggregation in R6/2 mice and improved neurological performance 
[146]. These findings suggest that activation of Hsp70-facilitated disaggregation or degradation 
by upregulation of DNAJB1 and DNAJB2 is beneficial in polyQ disease. Similarly, DNAJB6 
over-expression reduced polyQ Htt inclusion formation in the brain of R6/2 mice, and improved 
both neurological function and lifespan [124]. The extent to which Hsp70 is required for the 
therapeutic effect of DNAJB6 is uncertain, however these results suggest decreased aggregation 
is beneficial in both cellular and animal models of polyQ disease. 
Over-expression of co-chaperones that promote degradation of polyQ proteins also has 
beneficial effects. For example, over-expression of CHIP in models of SBMA decreases polyQ 
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AR aggregation, increases polyQ AR ubiquitination, and enhances proteasomal degradation, 
leading to improved motor function [147, 148]. CHIP over-expression preferentially enhanced the 
proteasomal degradation of polyQ AR over wildtype, demonstrating the selectivity of Hsp70-
CHIP-facilitated ubiquitination for misfolded proteins. CHIP over-expression also increased 
polyQ Htt ubiquitination in cells [149] and increased survival in both zebrafish and cellular models 
of HD [149, 150]. Additionally, over-expression of CHIP has been shown to increase 
ubiquitination and proteasomal degradation of polyQ proteins in cellular models of SCA3 and 
SCA1, and to decrease toxicity in a Drosophila model of SCA1 [151]. Surprisingly, CHIP over-
expression readily increases the ubiquitination of both wild type and polyQ ATXN1 and ATXN3 
[145, 151, 152]. These findings contrast with studies utilizing other polyQ proteins that have 
demonstrated Hsp70-CHIP-mediated ubiquitination preferentially targets misfolded proteins. 
With respect to ATXN3, these findings may reflect its role as a deubiquitinating enzyme. Wild 
type ATXN3 forms a complex with CHIP, regulating its activity by modulating CHIP-
autoubiquitination [153]. Over-expression of the co-chaperone HIP, known to stabilize Hsp70 in 
the ADP state, also appears to enhance proteasomal degradation of polyQ proteins. HIP over-
expression increased polyQ AR proteasomal degradation in cells and decreased toxicity in a 
Drosophila model of SBMA [154]. Over-expression of HspB8 in cellular models of SBMA 
increased autophagy of polyQ but not wild type AR  [74]. Over-expression of HspB8 and BAG3 
also enhanced the autophagic degradation of polyQ Htt in cellular models [155]. As a whole, this 
body of literature demonstrates that the development of pharmacological chaperones that enhance 
Hsp70 mediated degradation through the UPS or autophagy may be therapeutically beneficial in 
polyQ disease. 
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Small molecules targeting Hsp70 
Numerous small molecule modulators of Hsp70 have been discovered (reviewed in detail 
in [156]); however, only a select few have been evaluated in cellular and animal models of polyQ 
disease (Table 1-2). Two major strategies have been evaluated thus far: activation of Hsp70-
facilitated disaggregation and proteasomal degradation. 
Activation of disaggregase activity 
The role of polyQ protein aggregation in disease pathogenesis is a subject of ongoing 
debate, as some evidence suggests that the formation of large aggregates protects cells from the 
toxic effects of soluble polyQ proteins [157]. For several polyQ diseases there is good evidence 
small oligomers are the toxic species [10]. It is also proposed that later stages of aggregation can 
contribute to toxicity through the sequestration of proteins critical to the maintenance of 
proteostasis [141]. Nevertheless, as discussed in the previous section, over-expression of co-
chaperones that promote Hsp70’s disaggregase activity has been shown to reduce toxicity in 
models of polyQ disease. Therefore, one therapeutic strategy for the treatment of 
neurodegenerative disease is to enhance the disaggregase activity of Hsp70 [158, 159], a function 
that is dependent on nucleotide cycling [160]. Nadler and colleagues discovered that the 
immunosuppressant 15-deoxyspergualin (15-DSG), a natural product isolated from Bacillus 
laterosporus, binds to Hsp70 [161, 162] at the EEVD domain on the C-terminus [163]. It was later 
determined by Brodsky and co-workers that 15-DSG enhanced the basal rate of Hsp70 ATPase 
activity but did not affect the stimulation of ATPase activity by J-domain proteins [164]. While 
the immunosuppressant activity of 15-DSG appeared to be due to Hsp70-dependent dysregulation 
of NF-κB signaling [165], numerous off target effects including binding to Hsp90 [166] made it 
difficult to use 15-DSG as a tool to investigate the impact of enhanced Hsp70 ATPase activity. 
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Brodsky and co-workers utilized an in vitro assay for Hsp70 ATPase activity to study the effect of 
compounds structurally similar to 15-DSG. Groups lead by Brodsky and Gestwicki have 
discovered that certain dihydropyrimidine compounds activate Hsp70 ATPase activity while 
others inhibit. Further adding to the complexity, some of the compounds require the presence of 
co-chaperones for their action [167–170]. 
The dihydropyrimidine SW02 activates Hsp70 ATPase activity [170] and decreases Aβ 
aggregation measured by Thioflavin T in an in vitro assay for Aβ aggregation [171]. In contrast, 
treatment with an inhibitor of ATPase activity, the dihydropyrimidine SW08, enhances Aβ 
aggregation. 115-7c, a compound structurally similar to SW02, was shown to bind the NBD of 
Hsp70 in close proximity to the binding site of Hsp40 [172]. Treatment of yeast and PC12 cells 
expressing polyQ Htt with SW02 decrease aggregation of polyQ Htt, while treatment with the 
ATPase inhibitor CE12 increased polyQ Htt aggregation [173]. However, in the same model, 
SW02 enhanced and CE12 decreased polyQ related toxicity [173]. This toxicity correlated with 
the effect each compound had on the level of proteins, with SW02 increasing and CE12 decreasing 
soluble polyQ protein. Consistent with these results, treatment of HeLa cells expressing tau with 
the Hsp70 ATPase activators SW02 and 115-7c increased tau levels, whereas ATPase inhibitors 
decreased tau levels by enhancing the proteasomal degradation of tau [174]. As a whole these 
studies suggest that enhancing the disaggregation activity of Hsp70 leads to toxicity by increasing 
levels of toxic soluble polyQ species. 
Enhancing proteasomal degradation 
Studies with dihydropyrimidine-containing inhibitors of Hsp70 ATPase demonstrated that 
pharmacological enhancement of Hsp70-facilitated proteasomal degradation was feasible. Most 
Hsp70 ATPase inhibitors have been discovered by use of in vitro ATPase activity assays. These 
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assays look at the ability of Hsp70 to hydrolyze nucleotide with or without the presence of J-
domain and NEF co-chaperones. The benzothiazine containing compound methylene blue (MB) 
and it’s analogue azure C (AC) were discovered to inhibit ATPase activity of the Hsp70 bacterial 
homolog DnaK [170]. MB inhibits Hsp70 through oxidation of Cys306 (a residue not present on 
Hsc70), which prevents nucleotide binding [175] These compounds were first evaluated for their 
effect on tau. MB and AC were shown to decrease tau levels in HeLa cells, an action that is 
enhanced by the over-expression of Hsp70 and decreased by inhibition of the proteasome [174], 
and MB reduced tau aggregation and soluble tau levels in a mouse model of human tauopathy 
[176]. While it has been demonstrated that MB enhances the proteasomal degradation of tau, this 
effect has not translated to polyQ-containing Hsp90 client proteins. For example, inhibition of 
Hsp70 by MB decreases proteasomal degradation of polyQ AR in HeLa cells [43]. Inhibition of 
Hsp70-mediated proteasomal degradation by MB also induces autophagy in HeLa cells, enhancing 
the autophagy of N-terminal polyQ AR fragments lacking the ligand binding domain. 
Additionally, MB and AC increased levels of ATXN3 in a cellular model of SCA3 [145]. MB 
demonstrated a clinical benefit in an extrapolated phase II clinical trial of  patients with moderate 
and mild Alzheimer’s disease [177]. However, MB has numerous actions unrelated to Hsp70, 
including inhibition of tau-tau interactions [178] and induction of tau autophagy [179]. Therefore, 
it is difficult to determine the extent to which inhibition of Hsp70 contributed to clinical benefit. 
MB has also been studied in models of HD; MB reduced aggregation and prevented neurotoxicity 
in a Drosophila model and decreased levels of insoluble Htt in R6/2 mice [180]. In both models 
MB also increased levels of BDNF. BDNF levels have been shown to be protective in HD, thus it 
is unclear if the positive effects of MB were related to its action on Hsp70.   
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MKT-077 is a rhodacyanine dye derivative discovered by the Fuji-Chemical Company to 
have anti-cancer activity [181–184]. A lipophilic cation imparts a positive charge on MKT-077 
causing the compound to be retained in cancer cell mitochondria, leading to mitochondrial 
dysfunction and contributing to its anti-cancer activity [183]. MKT-077 was taken into a phase I 
clinical trial, however it caused renal toxicity in patients and its clinical development was halted 
[185]. It was later discovered that MKT-077 binds to numerous species of the Hsp70 family 
including Hsc70 [186] and mtHsp70 [187]. In search of more clinically applicable compounds, 
numerous MKT-077 derivatives have been created [182, 188–191]. The MKT-077 derivative YM-
01 has decreased retention in the mitochondria and increased localization to the cytosol, factors 
that are thought to contribute to improved potency in various cancer cells [182, 192]. MKT-077 
and its derivatives bind selectively to the ADP state of Hsp70 at an allosteric site on the NBD, 
located within the interface of subdomains IA and IIA [191, 193, 194]. MKT-077 does not compete 
with nucleotide binding to Hsp70 [193, 195] and does not appear to alter basal ATPase activity 
[188, 196]. However, MKT-077 significantly decreases J-protein stimulated ATPase activity [188, 
196]. 
In addition to anti-cancer activity, MKT-077 and YM-01 have also been shown to enhance 
the degradation of proteins implicated in neurodegenerative disease including polyQ AR and tau 
(reviewed in [10, 11, 46]). For example, MKT-077 and YM-01 reduced tau levels in primary 
neurons and brain slices [196]. YM-01 also reduced the levels of polyQ AR in cells and alleviated 
polyQ AR-mediated toxicity in a Drosophila model of SBMA [154]. YM-01 was shown to 
substitute for HIP in an in vitro assay of Hsp70-dependent activation of neuronal nitric oxide 
synthase [197], suggesting that, like HIP, it may stabilize the ADP-bound conformation of Hsp70. 
Consistent with this hypothesis, HIP competes with YM-01 for binding to Hsp70, and partial 
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trypsin proteolysis experiments have demonstrated YM-01 promotes an ADP-like conformation 
of Hsp70 [154]. Notably, preliminary studies suggest YM-01 does not inhibit other functions of 
the Hsp90/Hsp70 chaperone machinery, including GR-Hsp90 heterocomplex assembly and steroid 
binding [154]. These findings suggest that stabilization of the ADP state of Hsp70 may promote 
the degradation of damaged client proteins without abolishing other functions of the Hsp90 and 
Hsp70 chaperone complex. 
Conclusion 
Hsp70 has been established as an attractive therapeutic target in polyQ disease, and 
numerous studies, in both cellular and animal models, demonstrate that the enhancement of Hsp70 
activity by the over-expression of co-chaperones can decrease polyQ protein aggregation and 
increase polyQ protein degradation. Therefore, small molecules that target Hsp70 are being 
investigated in hopes of discovering a “pharmacological co-chaperone” that can enhance Hsp70’s 
protein quality control functions. Compounds that increase Hsp70 ATPase activity have been 
shown to reduce polyQ aggregation, but are also associated with increased toxicity. Compounds 
that inhibit Hsp70 ATPase activity have given mixed results, with some compounds increasing 
and others decreasing proteasomal degradation of polyQ proteins. Additionally, some inhibitors 
of Hsp70 ATPase activity have been shown to perturb other functions of the Hsp90/Hsp70 
chaperone machinery, including the maturation of steroid receptors, and this approach has not been 
pursued. These findings demonstrate that a major obstacle in development of Hsp70 modulators 
for the treatment of polyQ disease will be designing compounds that selectively enhance Hsp70’s 
protein quality control functions while leaving other functions critical to cell survival untouched. 
Preliminary results suggest that compounds that stabilize the ADP state of Hsp70, such as YM-01, 
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may be able to selectively promote proteasomal degradation of already unfolded proteins, 
including polyQ proteins, and alleviate toxicity without abolishing other Hsp70 functions. 
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Tables & Figures 
 
Figure 1-1. The activity of Hsp70 is driven by a nucleotide-dependent conformational cycle 
and is regulated by co-chaperones. 
(A) Binding of ATP promotes a closed state of Hsp70 where the SBD is docked to the NBD, 
locking Hsp70 into a conformation with low affinity for misfolded protein. (B) ATP hydrolysis to 
ADP induces a large conformational change, increasing the affinity of Hsp70 for misfolded 
protein. DNAJ binds to and recruits substrate to Hsp70, in addition to stimulating Hsp70 ATP 
hydrolysis. (C) Nucleotide exchange promotes the release of protein from Hsp70, and allows the 




Figure 1-2. Proposed mechanism for regulation of polyQ AR protein quality control by 
Hsp90/70 chaperone machinery in SBMA. 
Hsp90 and Hsp70, in cooperation with a multi-protein machinery including HOP, facilitate steroid 
insertion (A), promoting misfolding and subsequent aggregation of polyQ AR. PolyQ AR is 
translocated to the nucleus by an Hsp90-immunophilin-dynein complex (B), where it forms 
nuclear aggregates. Hsp70 facilitates the CHIP-dependent ubiquitination of poly QAR, targeting 
the protein for degradation by the proteasome (C); the co-chaperones DNAJB2 and BAG3 promote 
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proteasomal degradation of ubiquitinated proteins. PolyQ AR that escapes Hsp70/CHIP-dependent 
ubiquitination and degradation via (C) forms small oligomers that coalesce into aggregates that are 
subject to disaggregation by the Hsp70-Hsp110-J-domain complex (D). The CHIP-Hsp70-BAG3-
HspB8 complex targets polyQ AR to the aggresome leading to degradation of polyQ AR in the 




Table 1-1. Proposed effect of co-chaperones on Hsp70-facilitated protein quality of polyQ proteins. 
Co-chaperone Effect  Ref. 
J-domain containing protein (DNAJ)  
DNAJB1 Decreases aggregation [80, 133, 77]  
Targets Hsp70 substrate to the proteasome [93, 143] 
DNAJB2 Recruits substrate to Hsp70 [51] 
 Targets Hsp70 substrate to the proteasome [51,52] 
DNAJB6 Decreases aggregation* [84, 85] 
Nucleotide exchange factor (NEF)  
BAG1 Releases Hsp70 substrate to the proteasome  [53, 54] 
BAG3 Facilitates the degradation of Hsp70 substrate by autophagy [72, 111] 
Hsp110 Decreases aggregation [76, 77] 
Tetratricopeptide repeat (TPR) containing proteins    
CHIP 
Ubiquitinates Hsp70 substrate and promotes degradation by the proteasome or 
autophagy [50, 53, 150] 
HIP Stabilizes ADP state of Hsp70 and promotes degradation by the proteasome [155] 
HOP Coordinates the interaction of Hsp70 and Hsp90 [40] 
Small heat shock protein   
HspB8 Facilitates the degradation of Hsp70 substrate by autophagy [71, 75] 
*Effect may be independent of cooperation with Hsp70 
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Table 1-2. Small molecules targeting Hsp70 and their effects in cellular and animal models of polyQ disease. 
Compound Structure Mechanism of action PolyQ protein Model system Outcome Ref. 
SW02 
 
ATPase activator Htt (46/103Q)  Yeast ↑ Toxicity [174] 
        ↑ Levels  
        ↓ Aggregation  
      PC12 cells − Toxicity [174] 
        ↓ Aggregation  
      
CE12 
 
ATPase inhibitor Htt (46/103Q)  Yeast ↓ Toxicity [174] 
        ↓ Levels  
        ↑ Aggregation  
      PC12 cells ↓ Toxicity [174] 
        ↑ Aggregation  
      
Methylene 
 
ATPase inhibitor AR (112Q) HEK293T cells ↑ Levels [43] 
Blue (MB)       ↓ Degradation  
    ATXN3 (22/71Q) HEK293T cells ↑ Levels [146] 
  Htt (103Q) Primary mouse neurons ↓ Toxicity [181] 
   R6/2 mice ↓ Toxicity  
   Drosophila ↓ Toxicity  
      
Azure C  
 
ATPase inhibitor ATXN3 (Q22/71) HEK293T Cells ↑ Levels [146] 
(AC)      
      
      
      
YM-01 
 
Stabilizes ADP state AR (112Q) PC12 cells ↓ Aggregation [155] 
        ↓ Total levels  
        ↑ Degradation   
    AR (52Q) Drosophila ↓ Toxicity   
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Chapter 2 : Activation of hsp70 leads to selective ubiquitination of dysfunctional forms of 
nNOS by CHIP 
Abstract 
Heme containing enzymes such as neuronal nitric oxide synthase (nNOS) are highly 
susceptible to damage by xenobiotics, and metabolism-based inactivation by specific 
environmental toxins or drugs leads to the rapid degradation of nNOS. In the course of studies on 
nNOS inactivation, we discovered that covalent alteration of the substrate-binding cleft leads to 
misfolding of the cleft and specific recognition by the heat shock protein 90 and 70 (Hsp90 and 
Hsp70) chaperone system. Hsp70 recruits CHIP (c-terminus of Hsp70 interacting protein), an E3 
ubiquitin ligase, leading to the selective ubiquitination and proteasomal degradation of the 
inactivated nNOS. Conversely, stabilization of the substrate-binding cleft by slowly reversible 
inhibitors protects nNOS from degradation. The ability of the Hsp90 and Hsp70 chaperone system 
to selectively recognize and degrade dysfunctional proteins makes it an attractive therapeutic 
target. We have shown that pharmacological activation of Hsp70 increases the ubiquitination of 
nNOS in cell-based systems. However, it has yet to be investigated if activation of Hsp70 
selectively increases the ubiquitination of dysfunctional forms nNOS. We developed a highly 
sensitive ELISA to measure nNOS ubiquitination and utilized this assay to establish a minimal 
purified protein system for the study of Hsp70-dependent ubiquitination of nNOS by CHIP in 
vitro. Utilizing well established pharmacological tools for manipulation of the substrate-binding 
cleft, we demonstrated that this purified protein system recapitulates the selective ubiquitination 
of dysfunctional forms of nNOS by Hsp70 that is observed in vivo. Activation of Hsp70 by the 
small molecule JG-98 increased the ubiquitination of dysfunctional nNOS, but not nNOS in its 
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native state. These findings demonstrate that pharmacological activation maintains the natural 
selectivity of Hsp70-dependent ubiquitination for dysfunctional proteins.  
Introduction 
Guanabenz (Wytensin) causes a dose- and time-dependent loss of neuronal nitric oxide 
synthase (nNOS) protein in penile tissue in vivo (1).  Guanabenz causes the inactivation of nNOS 
and triggers the ubiquitination and proteasomal degradation of the enzyme in cell-based systems 
(2). Studies with purified nNOS show that guanabenz acts in a metabolism-based manner leading 
to oxidation and loss of the cofactor tetrahydrobiopterin (BH4) present in the substrate-binding 
cleft of the enzyme (2,3).  Moreover, supplementation of BH4 abrogates the inactivation and the 
loss of nNOS protein in vivo as well as in cell-based systems (3). In the course of studies on how 
guanabenz causes this highly selective loss of nNOS in vivo, we discovered that nNOS is a client 
protein of Hsp90 (4) and is ubiquitinated by the Hsp70 associated E3-ligase CHIP (c-terminus of 
Hsp70 interacting protein) (5).  We postulated that the Hsp90- and Hsp70-based quality control 
machinery recognizes conformational changes in the substrate-binding cleft leading to 
ubiquitination and proteasomal degradation, thus removing the BH4-depleted and dysfunctional 
nNOS (6).  It is noteworthy that depletion of BH4 from cells can trigger nNOS ubiquitination (7).  
Interestingly, the depletion of BH4 from nNOS leads to a deleterious form of the enzyme that can 
cause oxidative stress (8) and the removal of such a species by ubiquitination and proteasomal 
degradation would be beneficial.  Other metabolism-based inactivators that covalently alter the 
substrate-binding cleft through heme alkylation (9) as well as removal of the heme prosthetic group 
to form apo-nNOS (10,11) or a C331A mutation of nNOS with an altered active site conformation 
(12) are known to enhance the ubiquitination and degradation of nNOS.  These findings further 
support the notion that changes in the conformation of the substrate-binding cleft trigger 
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recognition and the selective ubiquitination and degradation of the dysfunctional nNOS.  Based in 
part on these studies, we wondered if activation of the Hsp70 might enhance the selective removal 
of deleterious client proteins.  We were able to show that Hip, an Hsp70 co-chaperone that 
promotes client protein binding, as well as a small molecule mimic of Hip, YM-01,  enhances the 
ubiquitination of nNOS in transfected HEK293 cells (13).  However, it is not known if activation 
of Hsp70 leads to ubiquitination of only the dysfunctional forms of nNOS.  In other words, does 
activation of Hsp70, which has been postulated as a potential therapeutic target (14), maintain the 
protein quality control function of the chaperone machinery.  In the current study, we apply our 
knowledge of altering the active-site cleft of nNOS to probe the selectivity of ubiquitination when 
Hsp70 is activated.  
In order to study how Hsp70 activation affects nNOS ubiquitination, we developed a facile 
and reproducible in vitro system based on ELISA detection of ubiquitin conjugates that was more 
sensitive and reproducible than previously established western blotting techniques. We utilized 
this method to detect nNOS ubiquitination from a defined reaction mixture containing purified 
proteins, specifically optimized to ensure that we could reproducibly measure Hsp70:CHIP-
dependent ubiquitination. With the use of this system, we validated that known Hsp70 modulators 
such as Bag-1 and the YM-01 derivative JG-98, decreased and enhanced nNOS ubiquitination, 
respectively, as expected from their known actions on Hsp70.  The depletion of BH4 by auto-
inactivation of holo-nNOS or treatment with guanabenz lead to selective ubiquitination of the 
dysfunctional nNOS.  Conversely, stabilization of the substrate-binding cleft by slowly reversible 
inhibitors prevents nNOS ubiquitination. Treatment with JG-98 increased the ubiquitination of 
auto-inactivated nNOS but not nNOS in its native state. Thus, activation of Hsp70 maintains the 
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quality control function of the chaperone machinery and selects for dysfunctional nNOS while 
leaving the native protein intact.  
Materials and Methods 
Materials 
Adenosine 5′-triphosphate disodium salt hydrate (ATP), NADP+, glucose-6-phosphate, 
and glucose-6-phosphate-dehydrogenase and guanabenz were purchased from Sigma (St. Louis, 
MO). NG-Nitro-L-arginine was purchased from Cayman Chemical (Ann Arbor, MI). Sodium 
citrate was purchased from Fisher (Hampton, NH). Tetrahydrobiopterin (BH4) was purchased 
from Schircks Laboratories (Jona, Switzerland); BH4 was prepared in an aqueous solution 
containing equal molar dithiothreitol (DTT).   NG-Nitro-D-arginine and the mono- and 
polyubiquitinylated conjugates monoclonal antibody (FK2) (HRP conjugate) was purchased from 
Enzo Life Sciences (Farmingdale, NY). DYKDDDDK-tag (FLAG) Antibody Plate (Clear, 8X12 
strip) was purchased from GenScript (Piscataway, NJ). Ubiquitin activating enzyme (UBE1) was 
purchased from R&D Systems (Minneapolis, MN). The cDNA for expressing the GST-tagged 
UbcH5a (E2, ubiquitin carrier protein) was kindly provided by C. M. Pickart (Johns Hopkins 
Medical School, Baltimore, MD). cDNA for His-CHIP was kindly provided by C. Patterson 
(University of North Carolina, Chapel Hill). The cDNA for rat nNOS was kindly provided by Dr. 
Solomon Snyder (The Johns Hopkins Medical School, Baltimore). The cDNA for His-HA-tagged 
ubiquitin was from Dr. Yi Sun (University of Michigan, Ann Arbor). Human Hsp70 cDNA was 
kindly provided by Dr. David Toft (Mayo Clinic, Rochester, MN). Anti-nitric oxide synthase, 
brain (1409-1429) antibody produced in rabbit was purchased from Sigma (St. Louis, MO) and 
IRDye® 680RD goat anti-rabbit IgG secondary antibody was purchased from LI-COR 
Biosciences (Lincoln, Nebraska). 
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Expression and purification of proteins 
GST-tagged UbcH5a was bacterially expressed and purified by GSH-Sepharose affinity 
chromatography as previously described (15). His-CHIP and His-HA-ubiquitin were bacterially 
expressed and purified by nickel-nitrilotriacetic acid affinity chromatography as previously 
described (16). Murine BAG-1 was expressed in E. coli and purified as previously described (17). 
Hsp70 was bacterially expressed and purified by ATP-agarose chromatography, adapted from 
(18). Hsp90 was purified from rabbit reticulocyte lysate by sequential chromatography on DE52, 
hydroxylapatite, and ATP-agarose as previously described (18). Rat untagged and c-terminal 
FLAG-tagged apo-nNOS (19) was expressed in Sf9 insect cells using a recombinant baculovirus 
and purified by 2′,5′-ADP-sepharose and gel-filtration chromatography as described previously 
(4). The same method was utilized for the generation of FLAG-tagged holo-nNOS except that 
exogenous heme was added to Sf9 cells (4). The FLAG-tagged and untagged nNOS was 
ubiquitinated to the same degree by a purified protein system, as determined by western blot 
analysis (data not shown). The specific activity of the FLAG-tagged and untagged nNOS were 
equivalent, as determined by an oxyhemoglobin assay for the measurement of nitric oxide (19). 
in vitro ubiquitination reaction with purified proteins 
A purified protein ubiquitination reaction containing purified FLAG-tagged nNOS (0.2 
μM), Hsp70 (1.0 μM), his-CHIP (1.0 μM), E2 ubiquitin conjugating enzyme (1 μM), UBE1 (0.1 
μM), His-HA-ubiquitin (100 μM), and ATP (100 μM) in a total volume of 20 μl of 50 mM Hepes 
pH 7.4, 100 mM KCl, and 5 mM dithiothreitol (DTT) was incubated at 22 ˚C for the specified 
time. Ubiquitination reactions were then analyzed by ELISA or western-blotting as described 
below. 
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ELISA for nNOS ubiquitination 
Ubiquitination reactions were diluted in RIPA buffer to a final FLAG-nNOS concentration 
of 0.03 µM and 100 µl was added per well to an anti-FLAG 96-well plate. The plate was incubated 
for 4 hrs at 4 °C and then washed three times with RIPA buffer and once with PBS. Wells were 
treated with 100 µl anti-ubiquitin antibody conjugated to HRP (1:2,000). The plate was incubated 
for 1 hr at RT and then washed three times with PBS with 1% Tween20 and once with PBS. To 
measure HRP activity wells were treated with 100 µl TMB and absorbance at 370 nM was read 
every 7 seconds for 120 seconds. Raw values are shown in Fig. 2-2, but in all other figures the 
ELISA assay values were corrected for the non-nNOS-specific HRP signal, which is shown in Fig. 
2-2, and HRP activity was reported relative to an apo-nNOS untreated control. Statistical analysis 
was performed with GraphPad Prism (San Diego, CA); comparisons were made by one-way anova 
and curves were fit with linear regression or  non-linear sigmoidal 4PL. 
Western blotting 
Ubiquitination reactions were treated with 4X laemmli buffer and heated for 5 min at 100 
˚C. A total of 0.48 µg of FLAG-nNOS was loaded per well, resolved on a 5% (w/v) SDS-PAGE 
gel, and transferred to a polyvinylidene fluoride membrane for 2 h at 100 V. The blot was probed 
with an anti-nNOS primary antibody and a fluorescent anti-rabbit IgG secondary antibody. Higher 
molecular weight nNOS ubiquitin conjugates were quantified in Image Studio from LI-COR 
Biosciences (Lincoln, Nebraska) and values were corrected for background and reported as 
absorbance (arbitrary units). 
Alteration of the substrate-binding cleft of nNOS 
nNOS (1 µM) was incubated with or without an NADPH regenerating system containing 
NADP+ (400 µM), glucose-6-phosphate (10 mM), glucose-6-phosphate-dehydrogenase (1 
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unit/ml), and sodium citrate (10 µM), calmodulin (1 µM), and calcium (100 µM) in 50 mM Hepes 
pH 7.4, 100 mM KCl, and 5 mM dithiothreitol DTT for 30 min at 30 ºC. The pre-incubation was 
then diluted 5-fold into the purified protein in vitro ubiquitination reaction as described above. 
Results 
Purified protein system for the study of Hsp70-dependent ubiquitination of nNOS by CHIP 
We sought to establish an in vitro method to study Hsp70-dependent ubiquitination of 
nNOS by CHIP. In previous studies, western blotting was utilized to measure nNOS ubiquitination 
as shown in Fig. 2-1. Thus, based on previous studies we incubated FLAG-tagged apo-nNOS with 
a purified protein mixture containing the E1 ubiquitin activating enzyme, an E2 ubiquitin-
conjugating enzyme, the E3-ligase CHIP, and Hsp70 for increasing amounts of time at 22 ºC and 
quenched the reaction with sample buffer. Sample buffer treated reactions were then resolved by 
SDS-PAGE and visualized by western blotting with an anti-nNOS antibody (Fig. 2-1A). Higher 
molecular weight bands corresponding to nNOS-ubiquitin conjugates were then quantified (Fig. 
2-1B). Due to the large amount of nNOS used for visualization by western blotting, the unmodified 
nNOS band tended to obscure bands with one or a few ubiquitin added, favoring the measurement 
of higher molecular weight poly-ubiquitin bands (Fig. 2-1A). Additionally, there was a large error 
associated with the quantification of higher molecular weight poly-ubiquitin bands (Fig. 2-1B). 
To help overcome these limitations, we developed an ELISA to measure nNOS 
ubiquitination (Fig. 2-2). In this assay, FLAG-tagged apo-nNOS was incubated with the purified 
protein ubiquitination reaction mixture and then immobilized on an anti-FLAG 96-well plate. An 
anti-ubiquitin antibody conjugated to HRP, capable of detecting both mono- and poly-ubiquitin 
chains, was then used to probe for nNOS-ubiquitin conjugates and HRP activity was measured.  A 
shown in Fig. 2-2A, a time course was performed with ubiquitin reaction mixtures containing 
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FLAG-tagged (closed circles) or untagged apo-nNOS (open circles). The signal for the mixture 
containing FLAG-tagged apo-nNOS increased over time while the signal for the mixture 
containing untagged apo-nNOS did not, demonstrating the signal is dependent on FLAG-tagged 
nNOS. To assess the dependence of the signal on CHIP-mediated ubiquitination, FLAG-tagged 
apo-nNOS was incubated for 15 min with a complete ubiquitination reaction mixture or mixtures 
lacking CHIP or ubiquitin (Fig. 2-2B). Omission of CHIP or ubiquitin significantly decreased HRP 
activity. These results demonstrate that the signal generated by the ELISA is representative of 
CHIP-dependent ubiquitination of FLAG-tagged nNOS. Moving forward nNOS ubiquitination 
was calculated by correcting for the non-nNOS-specific signal, shown in Fig. 2-2A, and reported 
as HRP activity relative to untreated apo-nNOS control. 
One potential pitfall of utilizing a purified protein system to study Hsp70-dependent 
ubiquitination in vitro is that, in the absence of the spatial regulation present in the cell, Hsp70-
independent ubiquitination by CHIP may occur (20). Simple omission of Hsp70 from the mixture 
does not provide an accurate measure of Hsp70-depedence as it leads to direct ubiquitination by 
CHIP, independent of Hsp70. To overcome this experimental limitation, we utilized the Hsp70 co-
chaperone BAG-1M and the small molecule activator of Hsp70 JG-98 to probe the dependence of 
nNOS ubiquitination of Hsp70 function. Hsp70 function is driven by a conformational change 
resulting from the hydrolysis of ATP to ADP and the ADP-bound conformation of Hsp70 has high 
affinity for client proteins (21). BAG1-M can act as a nucleotide exchange factor, promoting the 
release of ADP from Hsp70 (22). While BAG1-M plays many roles in vivo (23), in vitro BAG1-
M has been shown to cause the dissociation of Hsp70 from client proteins (24). As shown in Fig. 
2-3A, the ubiquitination reaction mixture was treated with BAG1-M. Addition of BAG1-M caused 
a concentration-dependent decrease in apo-nNOS ubiquitination. The small molecule JG-98 is 
 56 
thought to stabilize Hsp70 in an ADP-like state and has been shown to antagonize the effect of 
BAG proteins (25). Treatment of the mixture with JG-98 (closed circles) caused a concentration-
dependent increase in nNOS ubiquitination (Fig. 2-3B). Treatment of the ubiquitination reaction 
mixture with the JG-258 (open circles), an inactive analog of JG-98, had no effect on nNOS 
ubiquitination (Fig. 2-3B). These findings demonstrate that the nNOS ubiquitination observed in 
this system is dependent on Hsp70 function.  
Hsp70 preferentially ubiquitinates dysfunctional nNOS 
We have demonstrated that alteration of the substrate-binding cleft by auto-inactivation 
and BH4 depletion triggers the ubiquitination and proteasomal degradation of nNOS (7,10,11), 
and that stabilization of the substrate-biding cleft by a slowly-reversible inhibitors protects nNOS 
from degradation (26). As shown in Fig. 2-4, we utilized well established conditions and 
pharmacological tools to manipulate the substrate-binding cleft of nNOS in order to determine if 
the minimal purified protein system for Hsp70-dependent ubiquitination preferentially 
ubiquitinates dysfunctional nNOS. 
Auto-inactivation increases the ubiquitination of nNOS in cells and stabilization of the 
substrate-binding cleft by L-NNA has been shown block this effect (26). Studies in vitro have 
demonstrated that incubation of holo-nNOS with NADPH and calmodulin, in the absence of 
substrate, causes auto-inactivation through the generation of reactive oxygen species within the 
heme-containing substrate-binding cleft (8). Under these previously established conditions, we 
investigated the effect of auto-inactivation of nNOS on its ubiquitination (Fig. 2-4A). Flag-tagged 
apo-nNOS or holo-nNOS was subjected to 30 min pre-incubation at 30 ºC with and without 
NADPH and calmodulin. In the absence of NADPH and calmodulin the ubiquitination of apo-
nNOS was significantly greater than holo-nNOS. This finding is consistent with studies in cell-
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based systems that demonstrate depletion of heme from the substrate-binding cleft of nNOS 
significantly increases ubiquitination (10). Pre-incubation with NADPH and calmodulin 
significantly increased the ubiquitination of holo-nNOS. To determine if this increase in 
ubiquitination reflects changes within the substrate-binding cleft, holo-nNOS was pre-incubated 
with NADPH and calmodulin in the presence of L-NNA (Fig. 2-4A). Treatment with L-NNA 
blocked the effect of NADPH and calmodulin on the ubiquitination of holo-nNOS. Treatment with 
the inactivate stereoisomer D-NNA had no effect on the increase in ubiquitination caused by 
NADPH and calmodulin. These findings demonstrate that alteration of the substrate-binding cleft 
through auto-inactivation of increases ubiquitination of holo-nNOS. 
As another way to alter the substrate-binding cleft we utilized the metabolism-based 
inactivator guanabenz. Guanabenz causes the oxidation and ensuing loss of BH4 from the 
substrate-binding cleft of nNOS (2,3), leading to rapid ubiquitination and proteasomal degradation 
in vivo (1). As shown in Fig. 2-4B, FLAG-tagged holo-nNOS was pre-incubated with or without 
NADPH, calmodulin, and 100 µM guanabenz.  Pre-incubation with NADPH, calmodulin, and 
guanabenz significantly increased ubiquitination of holo-nNOS. Additionally, co-treatment with 
BH4 abolished the effect of guanabenz (Fig 2-4B). These findings demonstrate that depletion of 
BH4 from the substrate-binding cleft increases the ubiquitination of holo-nNOS. These findings 
demonstrate that the minimal purified protein system for Hsp70-dependent ubiquitination 
successfully recapitulates the selective ubiquitination of dysfunctional nNOS that is observed in 
vivo. 
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Pharmacological activation of Hsp70 maintains the selectivity for ubiquitination of dysfunctional 
nNOS 
It appears that we have recapitulated the selective ubiquitination observed in cells with the 
minimal purified protein system we developed for Hsp70-dependent ubiquitination of nNOS by 
CHIP. We next sought to investigate if the activation of Hsp70 would alter the selectivity of the 
ubiquitination such that native functional forms of nNOS would also be ubiquitinated.  In order to 
address this, we assessed the effect of JG98 on holo-nNOS as our representative of native protein 
to that of the auto-inactivated holo-nNOS obtained by redox cycling with NADPH in the presence 
of calmodulin as shown above in Fig. 2-4A. As shown in Fig. 2-5, JG-98 caused a marked 
concentration-dependent increase in the ubiquitination of auto-inactivated holo-nNOS (closed 
circles) as would be expected from activation of Hsp70 shown earlier for apo-nNOS.  Interestingly, 
the native holo-nNOS was unaffected by JG98 (open circles). These results demonstrate that 
activation of Hsp70 by JG-98 does not abolish the selectivity of Hsp70-dependent ubiquitination.  
Discussion 
 The Hsp90 and Hsp70 chaperone system recognizes and selectively targets dysfunctional 
forms of nNOS for ubiquitination and proteasomal degradation (27). We have previously 
demonstrated that pharmacological activation of Hsp70 can increase the ubiquitination of nNOS 
(13). Therefore, activation of Hsp70 may provide a therapeutic strategy to remove disease-causing 
forms of nNOS, such as BH4-depleted nNOS which is implicated in cardiovascular disease. 
However, it had yet to be investigated if pharmacological activation abolishes the natural 
selectivity of Hsp70 ubiquitination for dysfunctional nNOS. This is an important area of 
investigation, as increased ubiquitination and degradation of functional nNOS in its native state 
could lead to toxicity. In this study we have established a minimal purified protein system for 
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Hsp70-dependent ubiquitination of nNOS by CHIP. We have demonstrated that alteration of the 
substrate-binding cleft by auto-inactivation and BH4 depletion increases nNOS ubiquitination in 
this system (Fig. 2-4). Conversely, we have shown stabilization of the substrate-binding cleft by 
the slowly reversible inhibitor L-NNA decreases nNOS ubiquitination in this system (Fig. 2-4A). 
Thus, we have successfully recapitulated the selective ubiquitination of dysfunctional nNOS by 
Hsp70 that is observed in vivo. Moreover, we have demonstrated that pharmacological activation 
of Hsp70 by the small molecule JG-98 increases the ubiquitination of auto-inactivated nNOS but 
does not affect nNOS in its native state (Fig. 2-5). These findings demonstrate that 
pharmacological activation by JG-98 maintains the natural selectively of Hsp70-dependent 
ubiquitination for dysfunctional nNOS. 
The Hsp90 and Hsp70 chaperones act as a protein quality control system for several 100 
client proteins, many of which are implicated in disease. As with nNOS, it is hypothesized that the 
chaperone system surveils unstable protein-folding clefts and selectively targets damaged proteins 
for degradation. This hypothesis is supported by studies demonstrating mutations affecting the 
steroid-binding cleft of the glucocorticoid receptor (GR) (28) or the nucleotide binding-cleft of the 
receptor tyrosine kinases ErbB-1 and ErbB-2 (HER1 and HER2) (29,30) have been shown to alter 
chaperone binding. Additionally, covalent alteration of the nucleotide-binding cleft of HER2 by 
an irreversible inhibitor was shown to increase HER2 degradation (31). Many proteins prone to 
misfolding and subsequent aggregation in neurons such as tau, α-synuclein, and huntingtin are 
Hsp90 and Hsp70 client proteins  (27). Thus, the therapeutic potential of Hsp70 activation is not 
limited to nNOS as it may also provide an approach to selectively degrade misfolded proteins for 







Figure 2-1. Measurement of nNOS ubiquitination by western blot. 
As described in methods, FLAG-tagged apo-nNOS was incubated with a purified protein 
ubiquitination reaction mixture for increasing amounts of time. Resulting ubiquitin-nNOS 
conjugates were visualized by western blot utilizing an anti-nNOS antibody (A), and higher 
molecular weight mono- and poly-ubiquitin-nNOS conjugates were quantified (B). Values are 
reported as mean + SD, n = 3. 
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Figure 2-2. Development of an ELISA to measure CHIP-dependent ubiquitination of FLAG-
tagged nNOS. 
As described in methods, FLAG-tagged apo-nNOS was incubated in a purified protein 
ubiquitination reaction mixture and immobilized on an anti-FLAG 96-well plate. The plate was 
probed with an anti-ubiquitin antibody conjugated to HRP and HRP activity was quantified. A) 
FLAG-tagged and untagged apo-nNOS were compared to assess the nNOS-dependence of the 
signal. FLAG-tagged (closed circles) and untagged (open circles) apo-nNOS were incubated for 
increasing amounts of time with the ubiquitination reaction mixture. B) To evaluate the 
dependence of the signal on CHIP-mediated ubiquitination, FLAG-tagged apo-nNOS was 
incubated for 15 min with the ubiquitination reaction mixture and mixtures lacking CHIP or 




Figure 2-3. nNOS ubiquitination is dependent on Hsp70 function. 
FLAG-tagged apo-nNOS was incubated with the purified protein ubiquitination reaction mixture 
for 15 min in the presence increasing concentrations of the Hsp70 co-chaperone BAG1-M (A), or 
the small molecule modulator of Hsp70 JG-98 (closed circles) and the structurally similar inactive 
analog JG-258 (open circles) (B). Values reported relative to untreated apo-nNOS and represent 




Figure 2-4. Alteration of the substrate-binding cleft by auto-inactivation and BH4 depletion 
increases Hsp70-dependent ubiquitination of holo-nNOS. 
To investigate the effect of substrate-binding cleft alteration on nNOS ubiquitination, pre-
incubations promoting autoinactivation and BH4 depletion of holo-nNOS were performed. FLAG-
tagged nNOS was pre-incubated for 30 min at 30 ºC and then incubated with the purified protein 
in vitro ubiquitination mixture for an additional 30 minutes. A) The effect of auotinactivation was 
investigated by pre-incubating FLAG-tagged apo- or holo-nNOS with NADPH and calmodulin 
with and without the slowly reversible inhibitor L-NNA or its inactive stereoisomer D-NNA. B) 
The effect of BH4 depletion was investigated by pre-incubating holo-nNOS with the mechanism 
based inactivator guanabenz, NADPH, and calmodulin with and without BH4. Values reported 
relative to untreated apo-nNOS and represent mean + SD, n=3-6. 
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Figure 2-5. Pharmacological activation of Hsp70 selectively increases the ubiquitination of 
auto-inactivated nNOS. 
To determine if pharmacological activation alters the selectivity of Hsp70-dependent 
ubiquitination, FLAG-tagged holo-nNOS was pre-incubated with and without NADPH and 
calmodulin. FLAG-tagged holo-nNOS was then transferred to the purified protein ubiquitination 
reaction mixture treated with increasing amounts of JG-98 and incubated for 15 min. Values 
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Chapter 3 : Development of a workflow for the discovery of small molecule activators of 
Hsp70-dependent ubiquitination 
Abstract 
The Hsp90 and Hsp70 chaperones act as a protein quality control system for over several 
100 client proteins, including many implicated in neurodegenerative disorders. We have 
demonstrated that activation of Hsp70 by the co-chaperone HIP, which is known to stabilize Hsp70 
in the ADP-bound state, or the HIP like compound YM-01 increases ubiquitination of neuronal 
nitric oxide synthase (nNOS) and promotes degradation of the polyglutamine androgen receptor 
(polyQ-AR). Additionally, activation of Hsp70 ameliorated disease phenotype in a Drosophila 
model of Kennedy’s disease, a rare muscular and neurodegenerative disorder caused by the 
misfolding and aggregation of polyQ-AR. Further pharmacological studies have been limited by 
the small number of compounds known to activate Hsp70. Thus, an innovative three-part workflow 
was developed to discover novel Hsp70 activators. In the first step of this workflow, a high-
throughput thermal shift assay was utilized to identify compounds that bind and thermostabilize 
Hsp70. Binding of ADP greatly thermostabilizes Hsp70, therefore we hypothesized this approach 
could detect compounds that promote the ADP-bound state. In the second step, a Hsp90 thermal 
shift counter screen was utilized to evaluate the selectivity of the Hsp70 thermostabilizers. In the 
third step, the functional effect of the Hsp70 thermostabilizers was investigated in an in vitro assay 
for Hsp70-dependent ubiquitination of nNOS by CHIP. Of the 44,447 small molecules screened 
one, compound #15, was shown to thermostabilize Hsp70 and activate Hsp70-dependent 
ubiquitination of nNOS. The discovery of compound #15 increases the structural diversity of small 
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molecules known to activate Hsp70 and may provide a valuable tool for the advancement of Hsp70 
activation as a therapeutic strategy.   
Introduction 
The heat shock protein 90 and 70 (Hsp90 and Hsp70) chaperone system regulates protein 
quality control for over 100 client proteins, including those implicated in neurodegenerative 
disease (1,2). Hsp90 and Hsp70 play opposing roles in the regulation of client protein degradation; 
Hsp90 stabilizes and protects proteins from degradation, whereas Hsp70 facilitates the 
ubiquitination of client proteins by chaperone associated E3 ligases such as CHIP (c-terminus of 
Hsp70 interacting protein) and subsequent degradation. We have demonstrated that 
overexpression of the Hsp70 co-chaperone HIP (Hsp70 interacting protein), known to stabilize 
Hsp70 in the ADP-bound state which has high affinity for client protein, increases Hsp70-
dependent ubiquitination of nNOS by CHIP in cells (3). Overexpression of HIP also increased 
clearance of the poly-glutamine (polyQ) containing androgen receptor (AR) in cells and improved 
a disease phenotype in a Drosophila model of Kennedy’s disease, a rare muscular and 
neurodegenerative disorder caused by the misfolding and aggregation of polyQ-AR (3). These 
findings, along with other genetic studies on a variety of client proteins (1), demonstrate that co-
chaperone activation of Hsp70-dependent ubiquitination and degradation is therapeutically 
beneficial in animal models. Thus, there is great interest in the development of small molecule co-
chaperones that can activate Hsp70-dependent ubiquitination. 
YM-01 is a small molecule shown to bind competitively with HIP and stabilize Hsp70 in 
an ADP-like state in vitro (3). We have demonstrated that YM-01 increases the ubiquitination of 
nNOS and enhances the clearance of polyQ-AR in cell-based systems (3).  YM-01 also increased 
polyQ-AR clearance and ameliorated a disease phenotype in a Drosophila model of Kennedy’s 
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disease (3). Additionally, YM-01 has been shown to decrease tau levels both in vitro and ex vivo 
(4).  These studies suggest that pharmacological activation of Hsp70-dependent ubiquitination and 
subsequent degradation of disease-causing proteins is a promising therapeutic strategy. However, 
YM-01 and further derivatives have failed to translate in other animal models due in part to a short 
half-life and mitochondrial toxicity. Thus, to advance the study of this therapeutic strategy there 
is a critical need for new small molecules that can enhance Hsp70-dependent ubiquitination.  
We found that ADP causes thermostabilization of Hsp70 and hypothesized this could be 
the basis of finding compounds that bind to Hsp70 and favor the ADP-bound state. To our 
knowledge this is the first time a thermal shift assay has been used for the discovery of Hsp70 
modulators. Therefore, we sought to design a thermal shift-based workflow that would allow us to 
identify novel Hsp70 modulators and directly probe their effect on Hsp70-dependent 
ubiquitination in vitro. We developed a high-throughput Hsp70 thermal shift assay and an Hsp90 
thermal shift counter screen to identify compounds that bind and thermostabilize Hsp70. To test 
the functional effect of Hsp70 thermostabilizers we established a purified protein system for the 
study of Hsp70-dependent ubiquitination of nNOS by CHIP, as previously described in chapter 2. 
Through the use of this workflow we successfully screened 44,447 small molecules from a 
structurally diverse library and identified, a novel Hsp70 modulator that selectively 
thermostabilizes Hsp70 and activates Hsp70-dependent ubiquitination in vitro.  
Materials and methods 
Materials 
1-Step™ slow TMB (3,3',5,5'-tetramethylbenzidine)-ELISA substrate solution, RIPA lysis 
and extraction buffer, and SYPRO™ Orange protein gel stain (5,000X Concentrate in DMSO) 
were purchased from Thermo Fisher Scientific (Waltham, MA). Adenosine 5′-triphosphate 
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disodium salt hydrate (ATP) and Adenosine 5′-diphosphate sodium salt (ADP) were purchased 
from Sigma (St. Louis, MO). Radicicol and VER-155008 were purchased from Cayman Chemical 
(Ann Arbor, MI). Mono- and polyubiquitinylated conjugates monoclonal antibody (FK2) (HRP 
conjugate) was purchased from Enzo Life Sciences (Farmingdale, NY). DYKDDDDK-tag 
(FLAG) Antibody Plate (Clear, 8X12 strip) was purchased from GenScript (Piscataway, NJ). 
Untreated rabbit reticulocyte lysate was purchased from Green Hectares (Oregon, WI). Ubiquitin 
activating enzyme (UBE1) was purchased from R&D Systems (Minneapolis, MN). The cDNA for 
expressing the GST-tagged UbcH5a (E2, ubiquitin carrier protein) was kindly provided by C. M. 
Pickart (Johns Hopkins Medical School, Baltimore, MD). cDNA for His-CHIP was kindly 
provided by C. Patterson (University of North Carolina, Chapel Hill). The cDNA for rat nNOS 
was kindly provided by Dr. Solomon Snyder (The Johns Hopkins Medical School, Baltimore). 
The cDNA for His-HA-tagged ubiquitin was from Dr. Yi Sun (University of Michigan, Ann 
Arbor). Human Hsp70 cDNA was kindly provided by Dr. David Toft (Mayo Clinic, Rochester, 
MN). JG-98 was kindly Provided by Jason Gestwicki (University of California, San Francisco, 
CA).  
Expression and purification of proteins 
GST-tagged UbcH5a was bacterially expressed and purified by GSH-Sepharose affinity 
chromatography as previously described (5). His-CHIP and His-HA-ubiquitin were bacterially 
expressed and purified by nickel-nitrilotriacetic acid affinity chromatography as previously 
described (6). Hsp70 was bacterially expressed and purified by ATP-agarose chromatography, 
adapted from (7). Hsp90 was purified from rabbit reticulocyte lysate by sequential chromatography 
on DE52, hydroxylapatite, and ATP-agarose as previously described (7). Rat FLAG-nNOS (8) 
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was expressed in Sf9 insect cells using a recombinant baculovirus and purified by 2′,5′-ADP-
sepharose and gel-filtration chromatography as described previously (9).  
Fluorescence thermal shift assay 
Medium-throughput 96-well format: The melting temperature (Tm) of Hsp70 was 
determined by a fluorescence thermal shift assay utilizing SYPRO orange dye (λex 470 nm /λem 
570 nm). A mixture of Hsp70 (1.5 µM), SYPRO orange (10X), and the small molecule to be tested 
was prepared in a buffer containing 50 mM potassium phosphate pH 7.4, 300 mM KCl, and 10% 
glycerol in a total volume of 25 µl. A CFX96 Real-Time PCR System (Biorad, Hercules, CA) was 
utilized to heat samples from 25 °C to 99 °C with a temperature increase of 0.3°C per minute while 
simultaneously measuring fluorescence. The Tm of the resulting melting curve was determined 
utilizing CFX Manager (Biorad). The Hsp90 thermal shift assay was carried out under the same 
conditions except that purified Hsp90 (1.5 µM) was used in place of Hsp70. 
High-throughput 384-well format: The thermal shift assay was adapted to a high 
throughput 384-well plate format and 45,000 compounds from the ChemDiv and Maybridge 
collection at the Center for Chemical Genomics were screened at 50 µM, under the same 
conditions described above except that the final volume was 10 µl. A QuantStudio 7 Flex Real-
Time PCR System (ThermoFisher, Waltham, MA) was utilized to heat samples from 25 °C to 80 
°C with a temperature increase of 0.03 °C per second while simultaneously measuring 
fluorescence. Protein Thermal Shift Software 1.3 (ThermoFisher, Waltham, MA) was utilized to 
determine the Tm of the resulting melting curves. Samples treated with DMSO or 1 mM ADP 
were utilized as negative and positive controls, respectively. A Z-factor was calculated as 
previously described in (10). An increase in Tm greater than 3 SDs was considered a positive hit.  
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in vitro ubiquitination of nNOS  
An ubiquitination reaction mixture containing purified FLAG-tagged nNOS (0.2 μM), 
Hsp70 (1.0 μM), his-CHIP (1.0 μM), E2 ubiquitin conjugating enzyme (1 μM), UBE1 (0.1 μM), 
His-HA-ubiquitin (100 μM), and ATP (100 μM) in a total volume of 20 μl of 50 mM Hepes pH 
7.4, 100 mM KCl, and 5 mM dithiothreitol (DTT) was incubated for 15 minutes, unless specified 
otherwise, at 22 ˚C. Reactions were then diluted in RIPA buffer to a final FLAG-nNOS 
concentration of 0.03 µM and 100 µl was added per well to an anti-FLAG 96-well plate. The plate 
was incubated for 4 hrs at 4 °C and then washed three times with RIPA buffer and once with PBS. 
Wells were treated with 100 µl anti-ubiquitin antibody conjugated to HRP (1:2,000). The plate 
was incubated for 1 hr at RT and then washed three times with PBS containing 1% Tween20 and 
once with PBS. Wells were treated with 100 µl TMB and absorbance at 370 nM was measured 
every 15 seconds for 120 seconds. HRP activity (mOD/min) was calculated by linear regression. 
HRP activity was corrected for the nNOS-independent signal, normalized to untreated control, and 
reported as nNOS ubiquitination. 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism (San Diego, CA); comparisons 
were made by one-way anova and curves were fit with a  non-linear sigmoidal 4PL. 
Results 
High-throughput screening for small molecule thermostabilizers of Hsp70 
We rationally designed a workflow for the identification of compounds that activate 
Hsp70-dependent ubiquitination, as outlined in Fig. 3-1. In the first step of this workflow, we 
utilized a thermal shift assay to screen for compounds that bind and thermostabilize Hsp70. In the 
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thermal shift assay purified Hsp70 is mixed with the fluorescent dye SYPRO™ orange and the 
temperature of the mixture is increased over time, resulting in an Hsp70 melting curve (Fig. 3-2A). 
As the mixture is heated Hsp70 begins to unfold exposing hydrophobic residues. Binding of 
SYPRO™ orange to these hydrophobic residues increases the fluorescence of the dye, which had 
previously been quenched by the aqueous buffer. Consequently, as the mixture is heated and 
Hsp70 unfolds an increase in fluorescence is observed. Upon further heating Hsp70 begins to 
aggregate, leading to a decrease in fluorescence. The inflection point of the increasing portion of 
this curve, known as the melting temperature (Tm), is a measure of Hsp70 thermostability. Binding 
of small molecules can cause either an increase or decrease in the thermostability of a protein. To 
validate the Hsp70 thermal shift assay, we investigated the effect of ADP on Hsp70 
thermostability. Addition of ADP caused a rightward shift in the melting curve of Hsp70 compared 
to untreated control (Fig. 3-2A). The effect was dependent on the concentration of ADP as shown 
by an increase in the Tm of Hsp70 (EC50 = 56.45 µM, Fig. 3-2B). These results are consistent 
with the substantial conformational change induced by the binding of ADP to Hsp70 (11). 
The Hsp70 thermal shift assay was adapted to a high-throughput platform (Fig. 3-2C). A 
Z-factor is a statistical characteristic for the evaluation of signal dynamic range and variation (10). 
Using 1 mM ADP as a positive control a Z-factor of 0.80 was obtained, this Z-score is well within 
the acceptable range. In collaboration with Drug Discovery and the Center for Chemical Genomics 
at the University of Michigan (Ann Arbor, MI), we screened 44,447 compounds from a collection 
of structurally diverse small molecules (Fig. 3-2C). Compounds that caused an increase in Tm 
greater than three standard deviations were considered positive in this assay; 2,126 positives were 
identified resulting in a hit ratio of 4.8% (Fig. 3-1). The hits were re-run at 5 different 
concentrations and 1,056 were found to produce a concentration-dependent response (Fig. 3-1). 
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Compounds with high EC50s and properties known to interfere with biochemical assays (such as 
known aggregators) were excluded, resulting in a collection of 105 high priority compounds (Fig. 
3-1). These compounds were then grouped by structure similarity and 35 representative 
commercially available compounds were chosen for re-purchase (Fig. 3-1). For validation, the re-
purchased compounds were tested at increasing concentrations, up to 500 µM, in the medium-
throughput Hsp70 thermal shift assay. Of the 35 re-purchased compounds 16 caused an increase 
in Tm greater than three standard deviations with the change in Tm ranging from 0.9 to 2.5 ºC 
(Fig. 3-1, Table 3-1). For 14 of the validated compounds an EC50 was successfully calculated with 
the lowest and highest EC50 being equal to 9.9 µM and 258 µM, respectively (Table 3-1). Two of 
the validated compounds resulted in a concentration-dependent increase in Tm that did not plateau 
by 500 µM and therefore an EC50 could not be determined for these compounds. 
Hsp90 counter screen to evaluate Hsp70 thermostabilizer selectivity 
An Hsp90 counter screen was utilized to investigate the selectivity of the Hsp70 
thermostabilizers identified by high-throughput screening. This assay is identical to the medium-
throughput Hsp70 thermal shift assay, except that purified Hsp90 is used in place of purified 
Hsp70. To validate the counter screen, we utilized the known Hsp90 inhibitor radicicol (12). 
Radicicol binds to the N-terminal nucleotide domain of Hsp90, inhibiting Hsp90 activity, but does 
not bind to Hsp70. As expected, addition of radicicol caused a rightward shift in the melting curve 
of Hsp90 (Fig. 3-3A) but not Hsp70 (Fig. 3-3B). Radicicol caused a significant increase in the Tm 
of Hsp90 and not Hsp70 (Fig. 3-3C) demonstrating the assay could identify compounds that bind 
and thermostabilize Hsp90. The 16 validated Hsp70 thermostabilizers were tested in the Hsp90 
counter screen, and the maximum change in Hsp90 Tm and corresponding EC50 were determined 
(Table 3-1). Seven of the validated Hsp70 thermostabilizers caused an increase in Hsp90 Tm 
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greater than three standard deviations, ranging from 2.3 to 15.6 ºC. As with the thermostabilization 
of Hsp70, the EC50 for the thermostabilization of Hsp90 by these compounds was in the mid-
micromolar range, 4.1 to 35.4 µM. Thus, only 9 of the 16 validated high-throughput screening 
positive demonstrated selectivity for Hsp70 over Hsp90 (Fig. 3-1, Table 3-1 highlighted in grey). 
It is noteworthy that the effects in this counter screen do not necessarily indicate a specific effect 
as non-specific effects on fluorescence would also be triaged at this step. 
Effect of Hsp70 thermostabilizers on Hsp70-dependent ubiquitination of nNOS by CHIP in vitro 
To assess the functional effect of the Hsp70 thermostabilizers, we utilized the minimal 
purified protein system for Hsp70-dependent ubiquitination of nNOS by CHIP and ELISA for the 
measurement of nNOS ubiquitination, which was developed in chapter 2. As shown in Fig. 3-4A, 
FLAG-tagged apo-nNOS was incubated at 22 ºC for 15 minutes with a purified protein 
ubiquitination reaction mixture that was treated with 50 µM of the Hsp70 thermostabilizers and 
nNOS ubiquitination was measured by ELISA. JG-98 (10 µM) was utilized as a positive control 
and resulted in a 2-fold increase in nNOS ubiquitination (Fig. 3-4A). Of the 9 selective Hsp70 
thermostabilizers identified by high-throughput screening only one, compound #15, caused a 
significant increase in nNOS ubiquitination at 50 µM (Fig. 3-1, Fig 3-4A). Moreover, we 
determined compound #15 caused a concentration-dependent 1.5-fold increase in nNOS 
ubiquitination with an EC50 of 11.26 µM (Fig. 3-4B). In comparison, JG-98 causes a 2-fold 
increase in nNOS ubiquitination with an EC50 of 7.44 µM (Chapter 2). For comparison, previously 
established thermal shift data (Table 3-1) were plotted in Fig. 3-4. Compound #15 caused a 
concentration-dependent increase in the Tm of Hsp70 (EC50 = 29.62 µM, Fig. 3-4C) but had no 
effect on the Tm of Hsp90 (Fig. 3-4D). Taken together, these results demonstrate that compound 
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#15 is a selective Hsp70 thermostabilizer that activates Hsp70-dependent ubiquitination on nNOS 
in vitro. 
Discussion 
Numerous genetic and limited pharmacological studies have demonstrated activation of 
Hsp70 increases the ubiquitination and subsequent degradation of disease-causing client proteins 
in cellular and animal models (1). However, further studies have been hindered by the limited 
number of small molecule activators of Hsp70-dependent ubiquitination available. Traditionally, 
high-throughput ATP hydrolysis assays have been utilized to identify novel Hsp70 modulators. 
However, effect on ATP hydrolysis does not always translate to activation of Hsp70-dependent 
ubiquitination. Additionally, compounds that affect ATP hydrolysis have the potential to interfere 
with critical Hsp70 functions dependent on nucleotide cycling. Thus, we utilized a high-throughput 
Hsp70 thermal shift assay and Hsp90 counter screen to identify compounds that bind Hsp70, 
independent of their effect on ATP hydrolysis. This high-throughput screening approach may 
provide a way to identify compounds with little or no effect on nucleotide cycling that are 
therefore, less likely to cause on-target side effects. Further studies will be needed to determine if 
Hsp70 thermostabilizers affect ATP hydrolysis.  
While the thermal shift assay provides an unbiased screening approach to identify 
compounds that that bind Hsp70, it offers no information on the effect of a compound on Hsp70-
dependent functions. In this workflow we directly probed the effect of the Hsp70 thermostabilizers 
identified by high-throughput screening on Hsp70-dependent ubiquitination in vitro utilizing the 
nNOS ubiquitination assay developed in chapter 2. The Hsp70 thermostabilizer compound #15 
caused an increase in Hsp70-dependent ubiquitination of nNOS by CHIP. Further studies are 
required to determine if compound #15 also increases the ubiquitination of nNOS in cells and if 
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this effect translates to other Hsp70 client proteins. Elucidation of the mechanism of action by 
which compound #15 activates Hsp70-dependent ubiquitination may shed light on the structural-
characteristics required for Hsp70 activation. These findings demonstrate that the workflow 
described in this study can be utilized to discover novel activators of Hsp70-dependent 
ubiquitination. Small molecules, like compound #15, identified by this workflow enhance the 
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Figure 3-1. Workflow for the discovery of small molecules that activate Hsp70-dependent 
ubiquitination of nNOS. 
In the first step of this workflow, a high-throughput thermal shift assay was utilized to screen for 
small molecules that bind and thermostabilize Hsp70. Next, a Hsp90 thermal shift counter screen 
was utilized to evaluate the selectivity of Hsp70 thermostabilizers. In the third step, the effect of 
selective Hsp70 thermostabilizers on Hsp70-dependent ubiquitination was investigated in an in 
vitro assay for nNOS ubiquitination. One activator of Hsp70-dependent ubiquitination was 
identified by this workflow.  
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Figure 3-2. High-throughput screen for small molecules that thermostabilize Hsp70. 
A thermal shift assay utilizing purified Hsp70 and the fluorescent dye SYPRO™ Orange was 
developed to identify compounds that bind and thermostabilize Hsp70. ADP, which causes a large 
conformational change in Hsp70 upon binding, was utilized to validate the assay. A) The effect of 
1 mM ADP on the melting curve of Hsp70. Values reported for representative control (Ctrl, black) 
and ADP (blue) treated melting curves. B) . The effect of ADP on the melting temperature (Tm) 
of Hsp70. Values reported as mean + SD, n= 3. C) The Hsp70 thermal shift assay was adapted to 
a high-throughput platform and 44,447 small molecules were screened; ADP (1 mM) was utilized 
as a positive control. Compounds that caused a change in Tm greater than three standard deviations 
(blue dashed line) were considered positive. 
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Table 3-1. Small molecule Hsp70 thermostabilizers identified by high-throughput 
screening. 
  Hsp70 thermal shift assay Hsp90 counter screen 
Compound # ΔTm (˚C) EC50 (µM) ΔTm (˚C) EC50 (µM) 
1 1.0 68.0 2.6 22.6 
2 1.8 15.1     
4 2.2  > 500     
5 1.9 12.1 15.2 35.4 
6 0.8 24.4     
10 0.9 11.9 2.3 4.1 
12 1.0 50.7     
15 1.8 29.6     
16 1.1 51.9     
24 1.0 25.8 8.8 11.9 
26 0.7 139.7 5.6 15.8 
30 2.5 15.7 7.7 4.1 
31 0.7 9.9     
32 1.3 > 500 7.7 33.5 
33 1.6 87.7     
35 1.1 10.2     




Figure 3-3. Hsp90 thermal shift counter screen to investigate selectivity of Hsp70 
thermostabilizers. 
A thermal shift counter screen utilizing purified Hsp90 and the fluorescent dye SYPRO™ Orange 
was developed to investigate the selectivity of the Hsp70 thermostabilizers identified by high-
throughput screening. The counter screen was validated using the known Hsp90 inhibitor radicicol. 
The effect of radicicol (10 µM) on the melting curve of Hsp90 (A) or Hsp70 (B) was investigated. 
Values reported for representative control (Ctrl, black) and plus radicicol (Rad, blue) melting 
curves. C) Effect of radicicol (10 µM) on the melting temperature (Tm) of Hsp90 and Hsp70. 
Values reported as mean + SD, n= 3. 
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Figure 3-4. A small molecule Hsp70 thermostabilizer activates Hsp70-dependent 
ubiquitination of nNOS by CHIP. 
The effect of the selective Hsp70 thermostabilizers on Hsp70-dependent ubiquitination was tested 
in vitro. FLAG-tagged nNOS was incubated with a purified protein ubiquitination reaction mixture 
and nNOS ubiquitination was measured by ELISA. A) The ubiquitination reaction mixture was 
treated with 50 µM of each Hsp70 selective thermostabilizers or JG-98 (10 µM) as a positive 
control. Compound #15 was the only selective Hsp70 thermostabilizer to significantly increase 
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nNOS ubiquitination. Values reported as mean + SD, n = 3-6. B) To further investigate the effect 
of compound #15 on Hsp70-depnent ubiquitination, the ubiquitination reaction mixture was 
treated with compound #15 at increasing concentrations (closed circles) or 10 µM JG-98 (open 
circle) as a positive control. Values reported as mean + SD, n = 3 Previous experiments 
demonstrated, compound #15 caused a concentration-dependent increase in the melting 
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Chapter 4 : Discussion 
This thesis discusses the pharmacology of heat shock protein 70 (Hsp70) activation. In 
chapter one, a comprehensive literature review establishes activation of Hsp70 as a promising 
therapeutic strategy in the treatment of polyglutamine (polyQ) disease, a group of diseases 
caused by the misfolding and aggregation of proteins containing abnormal polyQ expansions. 
Numerous genetic and limited pharmacological studies have demonstrated that activation of 
Hsp70 promotes the ubiquitination and subsequent proteasomal degradation of polyQ-containing 
proteins.  This review also reveals a need for more structurally diverse small molecule activators 
of Hsp70, in order to further the study of this therapeutic strategy. Thus, in chapter two and three 
an innovative workflow for the discovery of novel Hsp70 activators was developed as illustrated 
in chapter 3, figure 1. 
 In chapter two, a method was established to study activation of Hsp70-dependent 
ubiquitination in vitro. A highly sensitive ELISA was designed to measure nNOS ubiquitination, 
and this assay was critical to the development of a purified protein system for Hsp70-dependent 
ubiquitination of neuronal nitric oxide synthase (nNOS) by c-terminus of Hsp70-interacting 
protein (CHIP). To our knowledge this is the first purified protein system for solely Hsp70-
dependent ubiquitination of nNOS (free of non-specific ubiquitination by CHIP). Through the 
study of nNOS inactivation, pharmacological tools have been established manipulate the folding 
of the nNOS substrate biding cleft. With the use of these tools, it was demonstrated that this 
purified protein system re-capitulates the selective ubiquitination of misfolded nNOS observed in 
vivo.  Moreover, it was shown for the first time that pharmacological activation of Hsp70 
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increases the ubiquitination of misfolded nNOS while leaving nNOS in its native state 
untouched. This method allows for the direct testing of compounds on Hsp70-dependent 
ubiquitination, and therefore played a key role in the discovery of novel Hsp70 activators as 
described in chapter 3. 
 In chapter three, a high-throughput Hsp70 thermal shift assay and Hsp90 counter-screen 
were developed to identify small molecules that bind and thermostabilize Hsp70. Thermal shift 
assays have previously been used to characterize conformational changes in Hsp70, therefore it 
was hypothesized that compounds which promote an ADP-like conformation, known to have 
high affinity for misfolded proteins, could be identified by this approach. Traditional high-
throughput approaches have utilized ATP hydrolysis assays to identify novel Hsp70 modulators. 
However, compounds that alter ATP hydrolysis have the potential to interfere with critical 
housekeeping functions dependent on Hsp70 nucleotide cycling. Therefore, the thermal shift 
assay, which identifies Hsp70 modulators independent of their effect on ATP hydrolysis, may 
allow for the discovery of less toxic compounds. The purified protein system for Hsp70-
dependent ubiquitination of nNOS was then utilized to test the functional effect of the Hsp70 
thermostabilizers. Of the 44,447 compounds screened one compound, referred to as compound 
#15, was shown to activate Hsp70-dependent ubiquitination of nNOS. 
The effect of compound #15 on Hsp70 is previously undescribed and the compound is 
structurally distinct from known Hsp70 activators. Structure activity relationship studies have 
identified the structural determinants for binding of compound #15 to Hsp70. Therefore, the 
structure of compound #15 has not been disclosed in this thesis to protect potential intellectual 
property. Further studies in cellular and animal models of disease will investigate the therapeutic 
potential of compound #15. These will include further studies with nNOS, which is implicated in 
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heart disease, as well as other client proteins of the Hsp90 and Hsp70 chaperone system, 
including polyQ-containing proteins. 
In summary, this thesis has established an innovative workflow for the discovery of 
Hsp70 activators and this workflow has successfully identified a novel small molecule activator 
of Hsp70, compound #15. This compound increases the structural diversity of small molecules 
shown to activate Hsp70. Thus, compound #15, and future compounds discovered by this 
workflow, may provide crucial tools to advance the development of Hsp70 activation as a 
therapeutic strategy. 
